WO2017106638A1 - Identification de néogènes, fabrication et utilisation - Google Patents

Identification de néogènes, fabrication et utilisation Download PDF

Info

Publication number
WO2017106638A1
WO2017106638A1 PCT/US2016/067159 US2016067159W WO2017106638A1 WO 2017106638 A1 WO2017106638 A1 WO 2017106638A1 US 2016067159 W US2016067159 W US 2016067159W WO 2017106638 A1 WO2017106638 A1 WO 2017106638A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
hla
allele
mhc
tumor
Prior art date
Application number
PCT/US2016/067159
Other languages
English (en)
Inventor
Roman YELENSKY
Adnan Derti
Brendan BULIK-SULLIVAN
Jennifer BUSBY
Original Assignee
Gritstone Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201680080924.4A priority Critical patent/CN108601731A/zh
Priority to JP2018550664A priority patent/JP7114477B2/ja
Application filed by Gritstone Oncology, Inc. filed Critical Gritstone Oncology, Inc.
Priority to IL305238A priority patent/IL305238A/en
Priority to EP16876766.3A priority patent/EP3389630B1/fr
Priority to ES16876766T priority patent/ES2970865T3/es
Priority to RU2018124997A priority patent/RU2729116C2/ru
Priority to EP23207311.4A priority patent/EP4299136A3/fr
Priority to SG11201804957VA priority patent/SG11201804957VA/en
Priority to MX2018007204A priority patent/MX2018007204A/es
Priority to CA3008641A priority patent/CA3008641A1/fr
Priority to IL259931A priority patent/IL259931B2/en
Priority to AU2016369519A priority patent/AU2016369519B2/en
Priority to BR112018012374-9A priority patent/BR112018012374A2/pt
Priority to KR1020187020164A priority patent/KR20180107102A/ko
Publication of WO2017106638A1 publication Critical patent/WO2017106638A1/fr
Priority to PH12018501267A priority patent/PH12018501267A1/en
Priority to CONC2018/0007417A priority patent/CO2018007417A2/es
Priority to HK19100224.7A priority patent/HK1257865A1/zh
Priority to JP2022089465A priority patent/JP2022133271A/ja
Priority to AU2023204618A priority patent/AU2023204618A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
    • G09F19/00—Advertising or display means not otherwise provided for
    • G09F19/12—Advertising or display means not otherwise provided for using special optical effects
    • G09F19/16—Advertising or display means not otherwise provided for using special optical effects involving the use of mirrors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • Neoantigen identification manufacture, and use.
  • FIG. 1 A shows current clinical approaches to neoantigen identification.
  • FIG. IB shows that ⁇ 5% of predicted bound peptides are presented on tumor ceils.
  • FIG. IE shows probability of MHC -I presentation as a function of peptide length.
  • FIG. 1 G shows how the addition of features increases the model positive predictive value.
  • FIG. 2A is an overview of an environment for identifying likelihoods of peptide presentation in patients, in accordance with an embodiment.
  • FIG. 3 is a high-level block diagram illustrating the computer logic components of the presentation identification system, according to one embodiment.
  • FIG. 7 illustrates generating a presentation likelihood for a peptide in association with an MHC allele using an example network model.
  • FIG. 9 illustrates generating a presentation likelihood for a peptide in association with MHC alleles using example network models.
  • FIG. 10 illustrates generating a presentation likelihood for a peptide in association with MHC alleles using example network models.
  • FIG. 12 illustrates generating a presentation likelihood for a peptide in association with MHC alleles using example network models.
  • FIG. 13 illustrates performance results of various example presentation models.
  • FIG. 14 illustrates an example computer for implementing the entities shown in FIGS. 1 and 3.
  • tumor neoantigen is a neoantigen present in a subject's tumor cell or tissue but not in the subject's corresponding normal cell or tissue.
  • neoantigen-based vaccine is a vaccine construct based on one or more neoantigens, e.g., a plurality of neoantigens.
  • candidate neoantigen is a mutation or other aberration giving rise to a new sequence that may represent a neoantigen.
  • coding region is the portion(s) of a gene that encode protein.
  • coding mutation is a mutation occurring in a coding region.
  • ORF means open reading frame
  • NEO-ORF is a tumor-specific ORF arising from a mutation or other aberration such as splicing.
  • missense mutation is a mutation causing a substitution from one amino acid to another.
  • nonsense mutation is a mutation causing a substitution from an amino acid to a stop codon.
  • frameshift mutation is a mutation causing a change in the frame of the protein.
  • the term “indel” is an insertion or deletion of one or more nucleic acids.
  • the term percent "identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for m aximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.
  • sequence comparison typically one sequence acts as a reference sequence to which test sequences are compared.
  • test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981 ), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).
  • BLAST algorithm is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990).
  • Software for perforating BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • non-stop or read-through is a mutation causing the removal of the natural stop codon.
  • epitopope is the specific portion of an antigen typically bound by an antibody or T cell receptor.
  • immunogenic is the ability to elicit an immune response, e.g., via T cells, B cells, or both.
  • HLA binding affinity means affinity of binding between a specific antigen and a specific MHC allele.
  • the term "bait” is a nucleic acid probe used to enrich a specific sequence of DNA or RNA from a sample.
  • variant is a difference between a subject's nucleic acids and the reference human genome used as a control.
  • variant call is an algorithmic determination of the presence of a variant, typically from sequencing.
  • polymorphism is a germline variant, i.e., a variant found in all DNA-bearing cells of an individual.
  • allele is a version of a gene or a version of a genetic sequence or a version of a protein.
  • HLA type is the complement of HLA gene alleles.
  • peptidome is the set of all peptides presented by MHC-I or MHC-I1 on the cell surface.
  • the peptidome may refer to a property of a ceil or a collection of cells (e.g., the tumor peptidome, meaning the union of the peptidomes of all cells that comprise the tumor).
  • EL1SPOT Enzyme-linked immunosorbent spot assay - which is a common method for monitoring immune responses in humans and animals.
  • clinical factor refers to a measure of a condition of a subject, e.g., disease activity or severity.
  • “Clinical factor” encompasses all markers of a subject's health status, including non-sample markers, and/or other characteristics of a subject, such as, without limitation, age and gender.
  • a clinical factor can be a score, a value, or a set of values that can be obtained from evaluation of a sample (or population of samples) from a subject or a subject under a determined condition.
  • a clinical factor can also be predicted by markers and/or other parameters such as gene expression surrogates.
  • Clinical factors can include tumor type, tumor sub-type, and smoking history.
  • MHC major histocompatibility complex
  • HLA human leukocyte antigen, or the human MHC gene locus
  • NGS next-generation sequencing
  • PPV positive predictive value
  • TSNA tumor-specific neoantigen
  • FFPE formalin-fixed, paraffin- embedded
  • NMD nonsense-mediated decay
  • NSCLC non-small-cell lung cancer
  • DC dendritic cell.
  • one such method may comprise the steps of: obtaining at least one of exome, transcriptome or whole genome tumor nucleotide sequencing data from the tumor ceil of the subject, wherein the tumor nucleotide sequencing data is used to obtain data representing peptide sequences of each of a set of neoantigens, and wherein the peptide sequence of each neoantigen comprises at least one alteration that makes it distinct from the corresponding wild-type, parental peptide sequence; inputting the peptide sequence of each neoantigen into one or more presentation models to generate a set of numeri cal likelihoods that each of the neoantigens is presented by one or more MHC alleles on the tumor cell surface of the tumor cell of the subject or cells present in the tumor, the set of numerical likelihoods
  • the presentation model can comprise a statistical regression or a machine learning (e.g., deep learning) model trained on a set of reference data (also referred to as a training data set) comprising a set of corresponding labels, wherein the set of reference data is obtained from each of a plurality of distinct subjects where optionally some subjects can have a tumor, and wherein the set of reference data comprises at least one of: data representing exome nucleotide sequences from tumor tissue, data representing exome nucleotide sequences from normal tissue, data representing transcriptome nucleotide sequences from tumor tissue, data representing proteome sequences from tumor tissue, and data representing MHC peptidome sequences from tumor tissue, and data representing MHC peptidome sequences from normal tissue.
  • a machine learning e.g., deep learning
  • the reference data can further comprise mass spectrometry data, sequencing data, RNA sequencing data, and proteomics data for single-aliele cell lines engineered to express a predetermined MHC allele that are subsequently exposed to synthetic protein, normal and tumor human cell lines, and fresh and frozen primary samples, and T cell assays (e.g., ELISPOT).
  • the set of reference data includes each form of reference data.
  • the presentation model can comprise a set of features derived at least in part from the set of reference data, and wherein the set of features comprises at least one of alleie dependent-features and allele-independent features. In certain aspects each feature is included.
  • the samples can also include cell lines engineered to express a plurality of MHC class I or class II alleles.
  • the training data set may be generated based on performing or having performed nucleotide sequencing on a cell line to obtain at least one of exome, transcriptome, or whole genome sequencing data from the cell line, the sequencing data including at least one nucleotide sequence including an alteration.
  • the training data set may further include data associated with peptide-MHC binding stability measurements for at least one of the isolated peptides.
  • a method disclosed herein can also include encoding the peptide sequence using a one-hot encoding scheme.
  • a tumor vaccine including a set of selected neoantigens selected by performing the method comprising the stpes of: obtaining at least one of exome, transcriptome or whole genome tumor nucleotide sequencing data from the tumor cell of the subject, wherein the tumor nucleotide sequencing data is used to obtain data representing peptide sequences of each of a set of neoantigens, and wherein the peptide sequence of each neoantigen comprises at least one mutation that makes it distinct from the corresponding wild-type, parental peptide sequence; inputting the peptide sequence of each neoantigen into one or more presentation models to generate a set of numeri cal likelihoods that each of the neoantigens is presented by one or more MHC alleles on the tumor cell surface of the tumor cell of the subject, the set of numerical likelihoods having been identified at least based on received mass spectrometry data; and selecting a subset of the set of neoantigens
  • the samples can also include cell lines engineered to express a single MHC class 1 or class II allele.
  • a method disclosed herein can also include obtaining a set of training protein sequences based on the training peptide sequences by comparing the set of training peptide sequences via alignment to a database comprising a set of known protein sequences, wherein the set of training protein sequences are longer than and include the training peptide sequences.
  • the training data set may further include data associated with transcriptomes associated with the samples.
  • the training data set may further include data associated with genomes associated with the samples.
  • a method disclosed herein may also include logistically regressing the set of parameters.
  • a method disclosed herein may also include encoding the training peptide sequences using a left-padded one-hot encoding scheme.
  • a method disclosed herein can also include selecting a subset of neoantigens, wherein the subset of neoantigens is selected because each has an increased likelihood that it is presented on the cell surface of the tumor relative to one or more distinct tumor neoantigens.
  • a method disclosed herein can also include selecting a subset of neoantigens, wherein the subset of neoantigens is selected because each has a decreased likelihood that it is subject to inhibition via central or peripheral tolerance relative to one or more distinct tumor neoantigens.
  • a method disclosed herein can also include selecting a subset of neoantigens, wherein the subset of neoantigens is selected because each has a decreased likelihood that it is capable of inducing an autoimmune response to normal tissue in the subject relative to one or more distinct tumor neoantigens.
  • Peptides with mutations or mutated polypeptides arising from for example, splice- site, frameshift, readthrough, or gene fusion mutations in tumor cells can be identified by sequencing DNA, RNA or protein in tumor versus normal cells.
  • mutations can include previously identified tumor specific mutations. Known tumor mutations can be found at the Catalogue of Somatic Mutations in Cancer (COSMIC) database.
  • DASH dynamic allele-specific hybridization
  • MADGE microplate array diagonal gel electrophoresis
  • pyrosequencing oligonucleotide-specific ligation
  • TaqMan system as well as various DNA "chip” technologies
  • Affymetrix SNP chips These methods utilize amplification of a target genetic region, typically by PCR. Still other methods, based on the generation of small signal molecules by invasive cleavage followed by mass spectrometry or immobilized padlock probes and rolling- circle amplification. Several of the methods known in the art for detecting specific mutations are summarized below.
  • PCR based detection means can include multiplex amplification of a plurality of markers simultaneously. For example, it is well known in the art to select PCR primers to generate PCR products that do not overlap in size and can be analyzed simultaneously.
  • RNA molecules can be detected by using a specialized exonuclease-resistant nucleotide, as disclosed, e.g., in Mundy, C. R. (U.S. Pat. No. 4,656,127).
  • a primer complementary to the allelic sequence immediately 3' to the polymorphic site is permitted to hybridize to a target molecule obtained from a particular animal or human.
  • the polymorphic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease- resistant nucleotide derivative present, then that derivative will be incorporated onto the end of the hybridized primer. Such incorporation renders the primer resistant to exonuclease, and thereby permits its detection. Since the identity of the exonuclease-resistant derivative of the sample is known, a finding that the primer has become resistant to exonucleases reveals that the nucleotide(s) present in the polymorphic site of the target molecule is complementary to that of the nucleotide derivative used in the reaction. This method has the advantage that it does not require the determination of large amounts of extraneous sequence data.
  • a solution-based method can be used for determining the identity of a nucleotide of a polymorphic site.
  • WO91/02087 As in the Mundy method of U.S. Pat. No. 4,656, 127, a primer is employed that is complementary to allelic sequences immediately 3' to a polymorphic site. The method determines the identity of the nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide of the polymorphic site will become incorporated onto the terminus of the primer.
  • Goelet, P. et al. PCT Appln. No. 92/157112.
  • the method of Goelet, P. et al. uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site.
  • the labeled terminator that is incorporated is thus determined by, and complementary to, the nucleotide present in the polymorphic site of the target molecule being evaluated.
  • Cohen et al. Fernch Patent 2,650,840; PCT Appln. No.
  • die method of Goelet, P. et al. can be a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase.
  • GBA in that they utilize incorporation of labeled deoxynucieotides to discriminate between bases at a polymorphic site.
  • the signal is proportional to the number of deoxynucieotides incorporated, polymorphisms that occur in runs of the same nucleotide can result in signals that are proportional to the length of the run (Syvanen, A.-C, et al., Amer. J. Hum. Genet. 52:46-59 (1993)).
  • oligonucleotides 30-50 bases in length are covalently anchored at the 5' end to glass cover slips. These anchored strands perform two functions. First, they act as capture sites for the target template strands if the templates are configured with capture tails complementar ' to the surface-bound oligonucleotides. They also act as primers for the template directed primer extension that forms the basis of the sequence reading.
  • the capture primers function as a fixed position site for sequence determination using multiple cycles of synthesis, detection, and chemical cleavage of the dye-linker to remove the dye. Each cycle consists of adding the polymerase/labeied nucleotide mixture, rinsing, imaging and cleavage of dye.
  • polymerase is modified with a fluorescent donor molecule and immobilized on a glass slide, while each nucleotide is color-coded with an acceptor fluorescent moiety attached to a gamma-phosphate.
  • the system detects the interaction between a fluorescently-tagged polymerase and a fluorescently modified nucleotide as the nucleotide becomes incorporated into the de novo chain .
  • Other sequencing-by-synthesis technologies also exist.
  • a plurality of nucleic acid molecules being sequenced is bound to a support (e.g., solid support).
  • a capture sequence/universal priming site can be added at the 3' and/or 5' end of the template.
  • the nucleic acids can be bound to the support by hybridizing the capture sequence to a complementary sequence covalently attached to the support.
  • the capture sequence (also referred to as a universal capture sequence) is a nucleic acid sequence complementary to a sequence attached to a support that may dually serve as a universal primer.
  • a member of a coupling pair (such as, e.g., antibody/antigen, receptor/ligand, or the avidin-biotin pair as described in, e.g., US Patent Application No. 2006/0252077) can be linked to each fragment to be captured on a surface coated with a respective second member of that coupling pair.
  • sequence of the template is determined by the order of labeled nucleotides incorporated into the 3' end of the growing chain. This can be done in real time or can be done in a step-and-repeat mode. For real-time analysis, different optical labels to each nucleotide can be incorporated and multiple lasers can be utilized for stimulation of incorporated nucleotides.
  • Sequencing can also include oilier massively parallel sequencing or next generation sequencing (NGS) techniques and platforms. Additional examples of massively parallel sequencing techniques and platforms are the Iliumina HiSeq or MiSeq, Thermo PGM or Proton, the Pac Bio RS II or Sequel, Qiagen's Gene Reader, and the Oxford Nanopore MinlON. Additional similar current massively parallel sequencing technologies can be used, as well as future generations of these technologies.
  • a DNA or RNA sample can be obtained from a tumor or a bodily fluid, e.g., blood, obtained by known techniques (e.g. venipuncture) or saliva.
  • nucleic acid tests can be performed on dry samples (e.g. hair or skin).
  • a sample can be obtained for sequencing from a tumor and another sample can be obtained from normal tissue for sequencing where the normal tissue is of the same tissue type as the tumor.
  • a sample can be obtained for sequencing from a tumor and another sample can be obtained from normal tissue for sequencing where the normal tissue is of a distinct tissue type relative to the tumor.
  • Tumors can include one or more of lung cancer, melanoma, breast cancer, o varian cancer, prostate cancer, kidney cancer, gastric cancer, colon cancer, testicular cancer, head and neck cancer, pancreatic cancer, brain cancer, B-cell lymphoma, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, and T cell lymphocytic leukemia, non-small cell lung cancer, and small cell lung cancer.
  • protein mass spectrometry can be used to identify or validate the presence of mutated peptides bound to MHC proteins on tumor cells.
  • Peptides can be acid- eiuted from tumor ceils or from HLA molecules that are immunoprecipitated from tumor, and then identified using mass spectrometry.
  • Neoantigens can include nucleotides or polypeptides.
  • a neoantigen can be an RNA sequence that encodes for a polypeptide sequence.
  • Neoantigens useful in vaccines can therefore include nucleotide sequences or polypeptide sequences.
  • Disclosed herein are isolated peptides that comprise tumor specific mutations identified by the methods disclosed herein, peptides that comprise known tumor specific mutations, and mutant polypeptides or fragments thereof identified by methods disclosed herein.
  • Neoantigen peptides can be described in the context of their coding sequence where a neoantigen includes the nucleotide sequence (e.g., DNA or RNA) that codes for the related polypeptide sequence.
  • One or more polypeptides encoded by a neoantigen nucleotide sequence can comprise at least one of: a binding affinity with MHC with an IC50 value of less than lOOOnM, for MHC Class 1 peptides a length of 8-15, 8, 9, 10, 11, 12, 13, 14, or 15 ammo acids, presence of sequence motifs within or near the peptide promoting proteasome cleavage, and presence or sequence motifs promoting TAP transport.
  • One or more neoantigens can be presented on the surface of a tumor.
  • One or more neoantigens can be is immunogenic in a subject having a tumor, e.g., capable of eliciting a T cell response or a B ceil response in the subject.
  • One or more neoantigens that induce an autoimmune response in a subject can be excluded from consideration in the context of vaccine generation for a subject having a tumor.
  • the size of at least one neoantigenic peptide molecule can comprise, but is not limited to, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31 , about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 60, about 70, about 80, about 90, about 100, about 1 10, about 120 or greater amino molecule residues, and any range derivable therein.
  • the neoantigenic peptide molecules are equal to or less than 50 amino acids.
  • Neoantigenic peptides and polypeptides can be: for MHC Class I 15 residues or less in length and usually consist of between about 8 and about 11 residues, particularly 9 or 10 residues; for MHC Class II, 15-24 residues.
  • a longer peptide can be designed in several ways.
  • a longer peptide could consist of either: (1) individual presented peptides with an extensions of 2-5 amino acids toward the N- and C-terminus of each corresponding gene product; (2) a concatenation of some or all of the presented peptides with extended sequences for each.
  • sequencing reveals a long (> 10 residues) neoepitope sequence present in the tumor (e.g.
  • a longer peptide would consist of: (3) the entire stretch of novel tumor-specific amino acids— thus bypassing the need for compu tational or in vitro test-based selection of the strongest HLA -presented shorter peptide.
  • use of a longer peptide allows endogenous processing by patient ceils and may lead to more effective antigen presentation and induction of T ee 13 responses.
  • Neoantigenic peptides and polypeptides can be presented on an HLA protein.
  • neoantigenic peptides and polypeptides are presented on an HLA protein with greater affinity than a wild-type peptide.
  • a neoantigenic peptide or polypeptide can have an IC50 of at least less than 5000 nM, at least less than 1000 nM, at least less than 500 nM, at least less than 250 nM, at least less than 200 nM, at least less than 150 nM, at least less than 100 nM, at least less than 50 nM or less.
  • neoantigenic peptides and polypeptides do not induce an autoimmune response and/or invoke immunological tolerance when administered to a subject.
  • compositions comprising at least two or more neoantigenic peptides.
  • the composition contains at least two distinct peptides. At least two distinct peptides can be derived from the same polypeptide. By distinct polypeptides is meant that the peptide vary by length, amino acid sequence, or both.
  • the peptides are derived from any polypeptide known to or have been found to contain a tumor specific mutation. Suitable polypeptides from which the neoantigenic peptides can be derived can be found for example in the COSMIC database. COSMIC curates comprehensive information on somatic mutations in human cancer.
  • the peptide contains the tumor specific mutation. In some aspects the tumor specific mutation is a driver mutation for a particular cancer type.
  • Neoantigenic peptides and polypeptides having a desired activity or property can be modified to provide certain desired attributes, e.g., improved pharmacological
  • neoantigenic peptide and polypeptides can be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding, stability or presentation.
  • conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another.
  • substitutions include combinations such as Gly, Ala; Val, He, Leu, Met; Asp, Glu; Asn, Gin; Ser, Thr; Lys, Arg; and Phe, Tyr.
  • the effect of single amino acid substitutions may also be probed using D-amino acids.
  • Such modifications can be made using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany & Merrifield, The Peptides, Gross & Meienhofer, eds. ( .Y., Academic Press), pp. 1-284 (1979); and Stewart & Young, Solid Phase Peptide Synthesis, (Rockford, 111, Pierce), 2d Ed. (1984),
  • Modifications of peptides and polypeptides with various amino acid rnirnetics or unnatural amino acids can be particularly useful in increasing the stability of the peptide and polypeptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab Pharmacokin. 11 :291-302 (1986). Half- life of the peptides can be conveniently determined using a 25% human serum (v/v) assay. The protocol is generally as follows.
  • pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloracetic acid or ethanol . The cloudy reaction sample is cooled (4 degrees C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.
  • the peptides and polypeptides can be modified to provide desired attributes other than improved serum half-life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response.
  • Immunogenic peptides/T helper conjugates can be linked by a spacer molecule.
  • the spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions.
  • the spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids.
  • the optionally present spacer need not be comprised of the same residues and thus can be a hetero- or homo-oligomer.
  • the spacer will usually be at least one or two residues, more usually three to six residues.
  • the peptide can be linked to the T helper peptide without a spacer,
  • a neoantigenic peptide can be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the peptide.
  • the amino terminus of either the neoantigenic peptide or the T helper peptide can be acyiated.
  • Exemplar ⁇ ' T helper peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382- 398 and 378-389,
  • Proteins or peptides can be made by any technique known to those of skill in the art, including the expression of proteins, polypeptides or peptides through standard molecular biological techniques, the isolation of proteins or peptides from natural sources, or the ch emical synthesis of proteins or peptides.
  • the nucleotide and protein, polypeptide and peptide sequences corresponding to various genes have been previously disclosed, and can be found at computerized databases known to those of ordinary skill in the art.
  • One such database is the National Center for Biotechnology Information's Genbank and GenPept databases located at the National Institutes of Health website.
  • the coding regions for known genes can be amplified and/or expressed using the techniques disclosed herein or as would be known to those of ordinary skill in the art.
  • various commercial preparations of proteins, polypeptides and peptides are known to those of skill in the art.
  • a neoantigen includes a nucleic acid (e.g. polynucleotide) that encodes a neoantigenic peptide or portion thereof.
  • the polynucleotide can be, e.g., DNA, cDNA, PNA, CNA, RNA (e.g., mRNA), either single- and/or double-stranded, or native or stabilized forms of polynucleotides, such as, e.g., polynucleotides with a phosphorothiate backbone, or combinations thereof and it may or may not contain introns.
  • a still further aspect provides an expression vector capable of expressing a polypeptide or portion thereof.
  • Expression vectors for different cell types are well known in the art and can be selected without undue experimentation.
  • DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, DNA can be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector.
  • the vector is then introduced into the host through standard techniques. Guidance can be found e.g. in Sambrook et ai. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, ⁇ . ⁇ .
  • an immunogenic composition e.g., a vaccine composition, capable of raising a specific immune response, e.g., a tumor-specific immune response.
  • Vaccine compositions typically comprise a plurality of neoantigens, e.g., selected usmg a method described herein.
  • Vaccine compositions can also be referred to as vaccines.
  • a vaccine can contain between 1 and 30 peptides, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 different peptides, 6, 7, 8, 9, 10 11, 12, 13, or 14 different peptides, or 12, 13 or 14 different peptides.
  • a vaccine can contain between I and 100 or more nucleotide sequences, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, 100 or more different nucleotide sequences, 6, 7, 8, 9, 10 11, 12, 13, or 14 different nucleot
  • a vaccine can contain between 1 and 30 neoantigen sequences, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 ?
  • different peptides and/or polypeptides or nucleotide sequences encoding them are selected so that the peptides and/or polypeptides capable of associating with different MHC molecules, such as different MHC class I molecule.
  • one vaccine composition comprises coding sequence for peptides and/or polypeptides capable of associating with the most frequently occurring MHC class I molecules.
  • vaccine compositions can comprise different fragments capable of associating with at least 2 preferred, at least 3 preferred, or at least 4 preferred MHC class I molecules.
  • the vaccine composition can be capable of raising a specific cytotoxic T-ce!ls response and/or a specific helper T-cell response.
  • a vaccine composition can further comprise an adjuvant and/or a carrier.
  • a composition can be associated with a carrier such as e.g. a protein or an antigen-presenting cell such as e.g. a dendritic cell (DC) capable of presenting the peptide to a T-cell.
  • a carrier such as e.g. a protein or an antigen-presenting cell such as e.g. a dendritic cell (DC) capable of presenting the peptide to a T-cell.
  • a carrier such as e.g. a protein or an antigen-presenting cell such as e.g. a dendritic cell (DC) capable of presenting the peptide to a T-cell.
  • DC dendritic cell
  • Adjuvants are any substance whose admixture into a vaccine composition increases or otherwise modifies the immune response to a neoantigen.
  • Carriers can be scaffold structures, for example a polypeptide or a polysaccharide, to which a neoantigen, is capable of being associated.
  • adjuvants are conjugated covarrirely or non- covalently.
  • Tlie ability of an adjuvant to increase an immune response to an antigen is typically manifested by a significant or substantial increase in an immune-mediated reaction, or reduction in disease symptoms.
  • an increase in humoral immunity is typically manifested by a significant increase in the titer of antibodies raised to the antigen
  • an increase in T-cell activity is typically manifested in increased cell proliferation, or cellular cytotoxicity, or cytokine secretion.
  • An adjuvant may also alter an immune response, for example, by changing a primarily humoral or Th response into a primarily cellular, or Th response.
  • Suitable adjuvants include, but are not limited to 1018 ISS, alum, aluminium salts, Amplivax, AS 15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiqumiod, ImuFact IMP321, IS Patch, ISS, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel vector system, PLG microparticles, resiquimod, SRL172, Virosornes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon (Aqui
  • cytokines have been directly linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF-alpha), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T- lymphocytes (e.g., GM-CSF, IL-l and IL-4) (U.S. Pat. No. 5,849,589, specifically incorporated herein by reference in its entirety) and acting as immunoadjuvants (e.g., IL-l 2) (Gabriiovich D I, et al., J Immunother Emphasis Tumor Immunol. 1996 (6):414-418).
  • CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting.
  • Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.
  • CpGs e.g. CpR, Idera
  • Poly(I:C) e.g. polyi:CI2U
  • non-CpG bacterial DNA e.g., bacterial DNA
  • RNA as well as immunoactive small molecules and antibodies such as cyclophosphamide, sunitmib, bevacizumab, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafinib, XL- 999, CP-547632, pazopamb, ZD2171, AZD2171, ipilimumab, tremelimumab, and SC58175, which may act therapeutically and/or as a adjuvant.
  • the amounts and concentrations of adjuvants and additives can readily be determined by the skilled artisan without undue experimentation. Additional adjuvants include colony-stimulating factors, such as
  • Granulocyte Macrophage Colony Stimulating Factor GM-CSF, sargramostim.
  • a vaccine composition can comprise more than one different adjuvant.
  • a therapeutic composition can comprise any adjuvant substance including any of the above or combinations thereof. It is also contemplated that a vaccine and an adjuvant can be administered together or separately in any appropriate sequence.
  • a earner can be present independently of an adju vant.
  • the function of a carrier can for example be to increase the molecular weight of in particular mutant to increase activity or immunogenicity, to confer stability, to increase the biological activity , or to increase serum half-life.
  • a carrier can aid presenting peptides to T-celis.
  • a carrier can be any suitable carrier known to the person skilled in the art, for example a protein or an antigen presenting cell.
  • a carrier protein could be but is not limited to keyhole limpet hemocyanin, serum proteins such as transferrin, bovine serum albumin, human serum albumin, thyroglobulin or ovalbumin, immunoglobulins, or hormones, such as insulin or palmitic acid.
  • the carrier is generally a physiologically acceptable carrier acceptable to humans and safe.
  • tetanus toxoid and/or diptheria toxoid are suitable carriers.
  • the carrier can be dextrans for example sepharose.
  • Cytotoxic T-cells recognize an antigen in the form of a peptide bound to an MHC molecule rather than the intact foreign antigen itself.
  • the MHC molecule itself is located at the cell surface of an antigen presenting cell.
  • an activation of CTLs is possible if a trimeric complex of peptide antigen, MHC molecule, and APC is present.
  • a vaccine composition additionally contains at least one antigen presenting cell.
  • Neoantigens can also be included in viral vector-based vaccine platforms, such as vaccinia, fowlpox, self-replicating alpha vims, marabavirus, adenovirus (See, e.g., Tatsis et al., Adenoviruses, Molecular Therapy (2004) 10, 616— 629), or lenti virus, including but not limited to second, third or hybrid second/third generation lentivirus and recombinant lentivirus of any generation designed to target specific cell types or receptors (See, e.g., Hu et al., Immunization Delivered by Lenti iral Vectors for Cancer and Infectious Diseases, Immunol Rev.
  • viral vector-based vaccine platforms such as vaccinia, fowlpox, self-replicating alpha vims, marabavirus, adenovirus (See, e.g., Tatsis et al., Adenoviruses, Molecular Therapy (2004) 10, 616— 629),
  • this approach can deliver one or more nucleotide sequences that encode one or more neoantigen peptides.
  • the sequences may be flanked by non-mutated sequences, may be separated by linkers or may be preceded with one or more sequences targeting a subcellular compartment (See, e.g., Gros et al.. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nat Med. (2016) 22 (4):433-8, Stronen et al., Targeting of cancer neoantigens with donor-derived T cell receptor repertoires, Science.
  • Truncal peptides meaning those presented by all or most tumor subclones, will be prioritized for inclusion into the vaccine. 3" '
  • further peptides can be prioritized by estimating the number and identi ty of tum or subclones and choosing peptides so as to maximize the number of tumor subclones covered by the vaccine. 54 IV.A.2. Neoantigen prioritization
  • neoantigen filters After ail of the above above neoantigen filters are applied, more candidate neoantigens may still be available for vaccine inclusion than the vaccine technology can support. Additionally, uncertainty about various aspects of the neoantigen analysis may remain and tradeoffs may exist between different properties of candidate vaccine neoantigens.
  • an integrated multi-dimensional model can be considered that places candidate neoantigens in a space with at least the following axes and optimizes selection using an integrative approach.
  • presen tation of a set of neoantigens may lower the probability that a tumor will escape immune attack via downregulation or mutation of HLA molecules
  • a subject has been diagnosed with cancer or is at risk of developing cancer.
  • a subject can be a human, dog, cat, horse or any animal in which a tumor specific immune response is desired.
  • a tumor can be any solid tumor such as breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, and other tumors of tissue organs and hematological tumors, such as lymphomas and leukemias, including acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T cell lymphocytic leukemia, and B cell lymphomas.
  • a neoantigen can be administered in an amount sufficient to induce a CTL response.
  • a neoantigen can be administered alone or in combination with other therapeutic agents.
  • the therapeutic agent is for example, a chemotherapeutic agent, radiation, or immunotherapy . Any suitable therapeutic treatment for a particular cancer can be administered.
  • a subject can be further administered an anti- immunosuppressive/immunostmiuiaiory agent such as a checkpoint inhibitor.
  • the subject can be further administered an anti-CTLA antibody or anti-PD-i or anti-PD-Ll .
  • Blockade of CTLA-4 or PD-LI by antibodies can enhance the immune response to cancerous cells in the patient.
  • CTLA-4 blockade has been shown effective when following a vaccination protocol.
  • a neoantigen or its variant can be prepared for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection.
  • Methods of injection include s.c, i.d., i .p., i.m ., and i.v.
  • Methods of DNA or RNA injection include i.d., i.m., s.c, i.p. and i.v.
  • Other methods of administration of the vaccine composition are known to those skilled in the art.
  • a vaccine can be compiled so that the selection, number and/or amount of neoantigens present in the composition is/are tissue, cancer, and/or patient-specific For instance, the exact selection of peptides can be guided by expression patterns of the parent proteins in a given tissue. The selection can be dependent on the specific type of cancer, the status of the disease, earlier treatment regimens, the immune status of the patient, and, of course, the HLA-haplotype of the patient. Furthermore, a vaccine can contain individualized components, according to personal needs of the particular patient. Examples include varying the selection of neoantigens according to the expression of the neoantigen in the particular patient or adjustments for secondary treatments following a first round or scheme of treatment.
  • neoantigens with similar normal self-peptides that are expressed in high amounts in normal tissues can be avoided or be present in low amounts in a composition described herein.
  • the respective pharmaceutical composition for treatment of this cancer can be present in high amounts and/or more than one neoantigen specific for this particularly neoantigen or pathway of this neoantigen can be included.
  • compositions comprising a neoantigen can be administered to an individual already suffering from cancer.
  • compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the tumor antigen and to cure or at least partially arrest symptoms and/or complications.
  • An amount adequate to accomplish this is defined as "therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician. It should be kept in mind that compositions can generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations, especially when the cancer has metastasized. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of a neoantigen, it is possible and can be felt desirable by the treating physician to administer substantial excesses of these compositions.
  • administration can begin at the detection or surgical removal of tumors. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter.
  • compositions for therapeutic treatment are intended for parenteral, topical, nasal, oral or local administration.
  • a pharmaceutical compositions can be administered parenterally, e.g., intravenously, subcutaneously, intraderrnally, or intramuscularly.
  • the compositions can be administered at the site of surgical exiseion to induce a local immune response to the tumor.
  • compositions for parenteral administration which comprise a solution of the neoantigen and vaccine compositions are dissolved or suspended in an acceptable carrier, e.g., an aqueous carrier.
  • aqueous carriers can be used, e.g., water, buffered water, 0.9% saline, 0.3% glycine, hyaluronic acid and the like. These compositions can be sterilized by conventional, well known sterilization techniques, or can be sterile filtered. The resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • Neoantigens can also be administered via liposomes, which target them to a particular cells tissue, such as lymphoid tissue. Liposomes are also useful in increasing half- life. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the neoantigen to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions.
  • a receptor prevalent among lymphoid cells such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions.
  • liposomes filled with a desired neoantigen can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic compositions.
  • Liposomes can be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9; 467 ( 1980), U.S. Pat. Nos. 4,235,871, 4,501,728, 4,501,728, 4,837,028, and 5,019,369,
  • a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system ceils.
  • a liposome suspension can be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.
  • nucleic acids encoding a peptide and optionally one or more of the peptides described herein can also be administered to the patient.
  • a number of methods are conveniently used to deliver the nucleic acids to the patient.
  • the nucleic acid can be delivered directiy, as "naked DNA". This approach is described, for instance, in Wolff et al.. Science 247: 1465-1468 (1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466.
  • the nucleic acids can also be administered using ballistic delivery as described, for instance, in U.S. Pat. No. 5,204,253.
  • Particles comprised solely of DNA can be administered.
  • DNA can be adhered to particles, such as gold particles.
  • Approaches for delivering nucleic acid sequences can include viral vectors, mRNA vectors, and DNA vectors with or without electroporation.
  • nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids.
  • cationic compounds such as cationic lipids.
  • Lipid-mediated gene delivery methods are described, for instance, in
  • Neoantigens can also be included in viral vector-based vaccine platforms, such as vaccinia, fowlpox, self-replicating alphavirus, marabavirus, adenovirus (See. e.g., Tatsis et al., Adenoviruses, Molecular Therapy (2004) 10, 616— 629), or ienti virus, including but not limited to second, third or hybrid second/third generation lenti virus and recombinant lentivirus of any generation designed to target specific cell types or receptors (See, e.g., Hu et al., Immunization Delivered by Lentiviral Vectors for Cancer and Infectious Diseases, Immunol Rev.
  • viral vector-based vaccine platforms such as vaccinia, fowlpox, self-replicating alphavirus, marabavirus, adenovirus (See. e.g., Tatsis et al., Adenoviruses, Molecular Therapy (2004) 10, 616— 629), or ienti virus,
  • this approach can deliver one or more nucleotide sequences that encode one or more neoantigen peptides.
  • the sequences may be flanked by non-mutated sequences, may be separated by linkers or may be preceded with one or more sequences targeting a subcellular compartment (See, e.g., Gros et al., Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nat Med. (2016) 22 (4):433-8, Stronen et al..
  • the minigene sequence is converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then cloned into a desired expression vector.
  • Single-nucleotide variants and indels will be detected from tumor DNA, tumor RNA and normal DNA with a suite of tools including: programs based on comparisons of tumor and normal DNA, such as Strelka 21 and Mutect 2 ; and programs that incorporate tumor DNA, tumor RNA and normal DNA, such as IJNCeqR, which is particularly advantageous in low-purity samples J .
  • IP immunoprecipitation
  • FIG. 2A is an overview of an environment 100 for identifying likelihoods of peptide presentation in patients, in accordance with an embodiment.
  • the environment 100 provides context in order to introduce a presentation identification system 160, itself including a presentation information store 165.
  • the presentation identification system 160 is able to receive nucleotide sequences of candidate neoantigens associated with a set of MHC alleles from tumor cells of a patient 110 and determine likelihoods that the candidate neoantigens will be presented by one or more of the associated MHC alleles of the tumor and/or induce immunogenic responses in the immune system of the patient 110.
  • Those candidate neoantigens with high likelihoods as determined by system 160 can be selected for inclusion in a vaccine 118, such an anti-tumor immune response can be elicited from the immune system of the patient 110 providing the tumor cells.
  • the presentation identification system 160 determines presentation likelihoods through one or more presentation models. Specifically, the presentation models generate likelihoods of whether given peptide sequences will be presented for a set of associated MHC alleles, and are generated based on presentation information stored in store 165. For example, the presentation models may generate likelihoods of whether a peptide sequence
  • the presentation information 165 contains information on whether peptides bind to different types of MHC alleles such that those peptides are presented by MHC alleles, which in the models is determined depending on positions of amino acids in the peptide sequences.
  • the presentation model can predict whether an unrecognized peptide sequence will be presented in association with an associated set of MHC alleles based on the presentation information 165.
  • FIG. 2 illustrates a method of obtaining presentation information, in accordance with an embodiment.
  • the presentation information 165 includes two general categories of information: ailele-interacting information and allele-noninteracting information.
  • Allele- interacting information includes information that influence presentation of peptide sequences that are dependent on the type of MHC allele.
  • Allele-noninteracting information includes information that influence presentation of peptide sequences that are independent on the type of MHC allele.
  • Ailele-interacting information primarily includes identified peptide sequences that are known to have been presented by one or more identified MHC molecules from humans, mice, etc. Notably, this may or may not include data obtained from tumor samples.
  • the presented peptide sequences may be identified from cells that express a single MHC allele. In tins case the presented peptide sequences are generally collected from smgle-aiiele cell lines that are engineered to express a predetermined MHC allele and that are subsequently- exposed to synthetic protein. Peptides presented on the MHC allele are isolated by techniques such as acid-elution and identified through mass spectrometry. FIG.
  • the direct association between a presented peptide and the MHC protein to which it was bound to is definitively known.
  • Allele-interacting information can also include measurements or predictions of binding affinity between a given MHC allele and a given peptide.
  • One or more affinity models can generate such predictions.
  • presentation information 165 may include a binding affinity prediction of ⁇ between the peptide YEMFNDKSF and the allele HLA-A*01 :01. Few peptides with IC50 > lOOOnm are presented by the MHC, and lower IC5G values increase the probability of presentation.
  • Allele-interacting information can also include the measured or predicted rate of the formation reaction for the peptide-MHC complex. Complexes that form at a higher rate are more likely to be presented on the cell surface at high concentration.
  • Allele-interacting information can also include the expression or activity levels of proteins involved in the process of post-translational modification, e.g., kinases (as measured or predicted from. RNA seq, mass spectrometry, or other methods).
  • proteins involved in the process of post-translational modification e.g., kinases (as measured or predicted from. RNA seq, mass spectrometry, or other methods).
  • Allele-interacting information can also include the expression levels of the particular MHC allele in the individual in question (e.g. as measured by RNA-seq or mass spectrometry)- Peptides that bind most strongly to an MHC allele that is expressed at high levels are more likely to be presented than peptides that bind most strongly to an MHC allele that is expressed at a low level .
  • Allele-interacting information can also include the overall neoantigen encoded peptide-sequence-independent probability of presentation by the particular MHC allele in other individuals who express the particular MHC allele.
  • Allele-interacting information can also include the overall peptide-sequence- independent probability of presentation by MHC alleles in the same family of molecules (e.g., HLA-A, HLA-B, HLA-C, HLA-DQ, HLA-DR, HLA-DP) in other individuals.
  • HLA-C molecules are typically expressed at lower levels than HLA-A or HLA-B molecules, and consequently, presentation of a peptide by HLA-C is a priori less probable than presentation by HLA-A or HLA-B 11.
  • Any MHC allele-noninteracting information listed in the below section can also be modeled as an MHC alieie-interacting information. VII.B.2. Allele-noninteracting Information
  • Allele-noninteracting infonnation can include C-terminal sequences flanking the neoantigen encoded peptide within its source protein sequence.
  • C-terminal flanking sequences may impact proteasomal processing of peptides.
  • the C-terminal flanking sequence is cleaved from the peptide by the proteasome before the peptide is transported to the endoplasmic reticulum and encounters MHC alleles on the surfaces of cells. Consequently, MHC molecules receive no infonnation about the C-terminal flanking sequence, and thus, the effect of the C-terminal flanking sequence cannot vary depending on MHC allele type.
  • presentation information 165 may include the C-terminal flanking sequence FOEIFNDKSLDKFJI of the presented peptide FJIEJFOESS identified from the source protein of the peptide.
  • Allele-noninteracting information can also include mRNA quantification measurements.
  • mRNA quantification data can be obtained for the same samples that provide the mass spectrometry- training data.
  • RNA expression was identified to be a strong predictor of peptide presentation.
  • the mRNA quantification measurements are identified from software tool RSEM. Detailed implementation of the RSEM software tool can be found at Bo Li and Colin N. Dewey, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12:323, August 2011.
  • the mRN A quantification is measured in units of fragments per kilobase of tran script per Million mapped reads (FPKM).
  • Allele-noninteracting information can also include the N-terminal sequences flanking the peptide within its source protein sequence.
  • Allele-noninteracting information can also include the level of expression of the proteasome, imniunoproteasome, thymoproteasome, or other proteases in the tumor cells (which may be measured by RNA-seq, proteome mass spectrometry, or
  • Allele-noninteracting information can also include the expression of the source gene of the peptide (e.g., as measured by RMA-seq or mass spectrometry). Possible optimizations include adjusting the measured expression to account for the presence of stromal cells and tumor-infiltrating lymphocytes within the tumor sample. Peptides from more highly expressed genes are more likely to be presented. Peptides from genes with undetectable levels of expression can be excluded from consideration.
  • Allele-noninteracting information can also include the probability that the source mRNA of the neoaritigen encoded peptide will be subject to nonsense-mediated decay as predicted by a model of nonsense-mediated decay, for example, the model from Rivas et al, Science 2015.
  • Allele-noninteracting information can also include a comprehensive catalog of features of the source protein as given in e.g. uniProt or PDB
  • These features may include, among others: the secondary and tertiary structures of the protein, subcellular localization 11, Gene ontology (GO) terms. Specifically, this information may contain annotations that act at the level of the protein, e.g., 5' UTR length, and annotations that act at the level of specific residues, e.g., helix motif between residues 300 and 310. These features can also include turn motifs, sheet motifs, and disordered residues.
  • Allele-noninteracting information can also include features describing the presence or absence of a presentation hotspot at the position of the peptide in the source protein of the peptide.
  • Allele-noninteracting information can also include the probability of presentation of peptides from the source protein of the peptide in question in other individuals (after adju sting for the expression level of the source protein in those individuals and the influence of the different HLA types of those individuals).
  • Allele-noninteracting information can also include the copy number of the source gene of the peptide in the tumor cells.
  • peptides from, genes that are subject to homozygous deletion in tumor cells can be assigned a probability of presentation of zero.
  • Allele-noninteracting information can also include the expression level of TAP in the tumor cells (w hich may be measured by RNA-seq, proteome mass spectrometry, immunohistochemistry). Higher TAP expression levels increase the probability of presentation of all peptides.
  • Allele-noninteracting information can also include known functionality of HLA alleles, as reflected by, for instance HLA allele suffixes.
  • HLA allele suffixes For example, the N suffix in the allele name HLA-A*24:09N indicates a null allele that is not expressed and is therefore unlikely to present epitopes; the full HLA allele suffix nomenclature is described at ht1ps://ww ⁇ ebi.ac.u pd/imgt/hla/nomenclature/suffixes.html.
  • Allele-noninteracting information can also include clinical tumor subtype (e.g., squamous lung cancer vs. non-squamous).
  • clinical tumor subtype e.g., squamous lung cancer vs. non-squamous.
  • Allele-noninteracting information can also include history of sunburn, sun exposure, or exposure to other mutagens.
  • Allele-noninteracting information can also include the typical expression of the source gene of the peptide in the relevant tumor type or clinical subtype, optionally stratified by driver mutation. Genes that are typically expressed at high levels in the relevant tumor type are more likely to be presented. [00300] Allele-noninteracting information can also include the frequency of the mutation in all tumors, or in tumors of the same type, or in tumors from individuals with at least one shared MHC allele, or in tumors of the same type in individuals with at least one shared MHC allele,
  • the list of features used to predict a probability of presentation may also include the annotation of the mutation (e.g., missense, read-through, frameshift, fusion, etc.) or whether the mutation is predicted to result in nonsense-mediated decay (NMD).
  • NMD nonsense-mediated decay
  • peptides from protein segments that are not translated in tumor cells due to homozygous early-stop mutations can be assigned a probability of presentation of zero. NMD results in decreased mRNA translation, which decreases the probability of presentation.
  • FIG. 3 is a high-level block diagram illustrating the computer logic components of the presentation identification system 160, according to one embodiment.
  • the presentation identification system 160 includes a data management module 312, an encoding module 314, a training module 3 6, and a prediction module 320.
  • the presentation identification system 160 is also comprised of a training data store 170 and a presentation models store 175.
  • Some embodiments of the model management system 160 have different modules than those described here. Similarly, the functions can be distributed among the modules in a different manner than is described here.
  • the data management module 312 generates sets of training data 170 from the presentation information 165.
  • Each set of training data contains a plurality of data instances, in which each data instance contains a set of independent variables t that include at least a presented or non-presented peptide sequence p one or more associated MHC alleles d associated with the peptide sequence p and a dependent variable V that represents information that the presentation identification system 160 is interested in predicting for new values of independent variables.
  • the dependent variable V is a binary label indicating whether peptide p l was presented by the one or more associated MHC alleles d.
  • the dependent variable f can represent any other kind of information that the presentation identification system 160 is interested in predicting dependent on the independent variables z l .
  • the dependent variable / may also be a numerical value indicating the mass spectrometry ion current identified for the data instance,
  • the peptide sequence p' for data instance is a sequence of k amino acids, in which ki may vary between data instances / ' within a range. For example, that range may be 8-15 for MHC class I or 9-30 for MHC class ⁇ , In one specific implementation of system 160, all peptide sequences p' in a training data set may have the same length, e.g. 9. The number of amino acids in a peptide sequence may vary depending on the type of MHC alleles (e.g., MHC alleles in humans, etc.). The MHC alleles d for data instance i indicate which MHC alleles were present in association with the corresponding peptide sequence p l ,
  • the data management module 312 may also include additional allele-interacting variables, such as binding affinity b' and stability s' predictions in conjunction with the peptide sequences p 1 and associated MHC alleles d contained in the training data 170.
  • the training data 170 may contain binding affinity predictions b l between a peptide p and each of the associated MHC molecules indicated in d.
  • the training data 170 may contain stability predictions s l for each of the MHC alleles indicated in d.
  • the data management module 312 may also include allele-noninteracting variables w such as C-terminai flanking sequences and mRNA quantification measurements in conjunction with the peptide sequences p
  • the data management module 312 also identifies peptide sequences that are not presented by MHC alleles to generate the training data 170. Generally, this involves identify ing the 'longer" sequences of source protein that include presented peptide sequences prior to presentation. When the presentation information contains engineered cell lines, the data management module 312 identifies a series of peptide sequences in the synthetic protein to which the cells were exposed to that were not presented on MHC alleles of the ceils.
  • the data management module 312 identifies source proteins from which presented peptide sequences originated from, and identifies a series of peptide sequences in the source protein that were not presented on MHC alleles of the tissue sample cells.
  • the data management module 312 may also artificially generate peptides with random sequences of amino acids and identify the generated sequences as peptides not presented on MHC alleles. This can be accomplished by randomly generating peptide sequences allows the data management module 312 to easily generate large amounts of synthetic data for peptides not presented on MHC alleles. Since in reality, a small percentage of peptide sequences are presented by MHC alleles, the synthetically generated peptide sequences are highly likely not to have been presented by MHC alleles even if they were included in proteins processed by cells.
  • FIG. 4 illustrates an example set of training data ⁇ 70 ⁇ , according to one embodiment.
  • the first 3 data instances in the training data 170 A indicate peptide presentation information from a single-allele cell line involving the allele HLA-C*01 :03 and 3 peptide sequences QCEIOWARE, F1EUHFW1, and FEWRHRJTRUJR.
  • the fourth data instance in the training data 170 A indicates peptide information from a multiple-allele cell line involving the alleles HLA-B*07:02, HLA-C*01 :03, HLA-A*01 :01and a peptide sequence QIEJOEIJE.
  • the first data instance indicates that peptide sequence QCEIOWARE was not presented by the allele HLA-C*01 :03.
  • the peptide sequence may be randomly generated by the data management module 312 or identified from source protein of presented peptides.
  • the training data 170 A also includes a binding affinity prediction of lOOOnM and a stability prediction of a half-life of lh for the peptide sequence-allele pair.
  • the training data ⁇ 70 ⁇ also includes allele-noninteracting variables, such as the C-terminal flanking sequence of the peptide FJELFISBOSJFIE, and a mRNA quantification measurement of 10 2 FPKM.
  • the fourth data instance indicates thai peptide sequence QIEJOEIJE was presented by one of the alleles HLA-B*07:02, HLA- C*01 :03, or HLA-A* 01 :01.
  • the training data 170 A also includes binding affinity predictions and stability predictions for each of the alleles, as well as the C-flanking sequence of the peptide and the mRNA quantification measurement for the peptide.
  • the encoding module 314 encodes information contained in the training data 170 into a numerical representation that can be used to generate the one or more presentation models.
  • the encoding module 314 one-hot encodes sequences (e.g., peptide sequences or C-terminal flanking sequences) over a predetermined 20-letter amino acid alphabet.
  • sequences e.g., peptide sequences or C-terminal flanking sequences
  • a peptide sequence p" with h, amino acids is represented as a ro vector of 20-k, elements, where a single element among p l 2o-(/-i)+j, ⁇ '2 ⁇ - ⁇ - ⁇ )+2, ...
  • p'lo-j that corresponds to the alphabet of the amino acid at the j-th position of the peptide sequence has a value of 1. Otherwise, the remaining elements have a value of 0.
  • a given alphabet ⁇ A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R.
  • the peptide sequence EAF of 3 amino acids for data instance may be represented by the row vector of 60 elements /
  • the C-terminal flanking sequence d can be similarly encoded as described above, as well as the protein sequence i , for MHC alleles, and other sequence data in the presentation information.
  • the encoding module 314 may further encode the peptides into equal-length vectors by adding a PAD character to extend the predetermined alphabet. For example, this may be performed by left-padding the peptide sequences with the PAD character until the length of the peptide sequence reaches the peptide sequence with the greatest length in the training data 170.
  • the encoding module 314 numerically represents each sequence as a row vector of (20+1)- k max elements.
  • the encoding module 314 also encodes the one or more MHC alleles d for data instance / as a row vector of m elements, in which each element /; /. 2, ... , «? corresponds to a unique identified MHC allele.
  • the elements corresponding to the MHC alleles identified for the data instance i have a value of 1 . Otherwise, the remaining elements have a value of 0.
  • HLA-A*01 :01, HLA-C*01 :08, HLA-B*07:02, HLA-C*01 :03 ⁇ may be represented by the row vector of 4 elements .
  • the number of MHC allele types can be hundreds or thousands in practice.
  • each data instance typically contains at most 6 different MHC allele types in association with the peptide sequence ⁇ ,.
  • the encoding module 314 also encodes the label y, for each data instance as a binary variable having values from the set of ⁇ 0, 1 ⁇ , in which a value of 1 indicates that peptide x' was presented by one of the associated MHC alleles a and a value of 0 indicates that peptide x l was not presented by any of the associated MHC alleles a .
  • the dependent variable v represents the mass spectrometry ion current
  • the encoding module 314 may additionally scale the values using various functions, such as the log function having a range of [- ⁇ , ⁇ for ion current values between [0, ⁇ ] .
  • the encoding module 314 may represent a pair of allele-interacting variables ⁇ 3 ⁇ 4 ! for peptide /?, and an associated MHC allele h as a row vector in which numerical representations of allele-interacting variables are concatenated one after the other.
  • the encoding module 314 may represent ⁇ 1 ⁇ 4' as a row vector equal to ⁇ p p l >/ ], ⁇ p l S ] , or where b ⁇ is the binding affinity prediction for peptide p, and associated MHC allele h, and similarly for 3 ⁇ 4 for stability.
  • one or more combination of allele-interacting variables may be stored individually (e.g., as individual vectors or matrices).
  • the encoding module 314 represents binding affinity information by incorporating measured or predicted values for binding affinity in the allele-interacting variables ⁇ 3 ⁇ 4'.
  • the encoding module 314 represents binding stability information by incorporating measured or predicted values for binding stability in the allele-interacting variables xn ,
  • the encoding module 314 represents binding on-rate information by incorporating measured or predicted values for binding on-rate in the allele-interacting variables
  • the vector 7* can be included in the allele-interacting variables x / .
  • the encoding module 314 represents RNA expression information of MHC alleles by incorporating RNA-seq based expression levels of MHC alleles in the allele-interacting variables ⁇ 3 ⁇ 4'.
  • the encoding module 314 may represent the allele-noninteracting variables w l as a row vector in which numerical representations of allele-noninteracting variables are concatenated one after the other.
  • w l may be a row vector equal to
  • w 1 is a row vector representing any other allele-noninteracting variables in addition to the C-terminai flanking sequence of peptide p' and the rnRNA quantification measurement m associated with the peptide.
  • w 1 is a row vector representing any other allele-noninteracting variables in addition to the C-terminai flanking sequence of peptide p' and the rnRNA quantification measurement m associated with the peptide.
  • one or more combination of allele-noninteracting variables may be stored individually (e.g., as individual vectors or matrices).
  • the encoding module 314 represents turnover rate of source protein for a peptide sequence by incorporating the turnover rate or half-life in the allele- noninteracting variables w'.
  • the encoding module 314 represents length of source protein or isoform by incorporating the protein length in the allele-noninteracting variables w'.
  • the encoding module 314 represents activation of
  • immunoproteasome by incorporating the mean expression of the immunoproteasome-specific proteasome subunits including the ⁇ 5,- subunits in the allele-noninteracting variables w
  • the encoding module 314 represents the RNA-seq abundance of the source protein of the peptide or gene or transcript of a peptide (quantified in units of FPKM, TPM by techniques such as RSEM) can be incorporating the abundance of the source protein in the allele-noninteracting variables .
  • the encoding module 314 represents the probability that the transcript of origin of a peptide will undergo nonsense-mediated decay (NMD) as estimated by the model in, for example, Rivas et. al. Science, 2015 by incorporating this probability in the allele-noninteracting variables w'.
  • NMD nonsense-mediated decay
  • the encoding module 314 represents the activation status of a gene module or pathway assessed via RNA-seq by, for example, quantifying expression of the genes in the pathway in units of TPM using e.g., RSEM for each of the genes in the pathway then computing a summary statistics, e.g., the mean, across genes in the pathway.
  • the mean can be incorporated in the allele-noninteracting variables w
  • the encoding module 314 represents the copy number of the source gene by incorporating the copy number in the allele-noninteracting variables w .
  • the encoding module 314 represents the TAP binding affinity by including the measured or predicted TAP binding affinity (e.g., in nanomolar units) in the allele-noninteracting variables w
  • the encoding module 314 represents TAP expression levels by including TAP expression levels measured by RNA-seq (and quantified in units of TPM by e.g., RSEM) in the allele-noninteracting variables w 1 .
  • the encoding module 314 represents tumor type as a length-one one-hot encoded vector over the alphabet of tumor types (e.g., NSCLC, melanoma, colorectal cancer, etc). These one-hot-encoded variables can be included in the allele-noninteracting variables w'.
  • the encoding module 314 represents MHC allele suffixes by treating 4-digit HLA alleles with different suffixes.
  • HLA-A*24:09N is considered a different allele from HLA-A*24:09 for the purpose of the model.
  • the probability of presentation by an N-suffixed MHC allele can be set to zero for all peptides, because HLA alleles ending in the N suffix are not expressed.
  • the encoding module 314 represents tumor subtype as a length- one one-hot encoded vector over the alphabet of tumor subtypes (e.g., lung adenocarcinoma, lung squamous cell carcinoma, etc). These onehot-encoded variables can be included in the allele-noninteracting variables w ! .
  • smoking history can be encoded as a length-one one-hot-enocded variable over an alphabet of smoking severity. For example, smoking status can be rated on a 1-5 scale, where 1 indicates nonsmokers, and 5 indicates current heavy smokers. Because smoking history is primarily relevant to lung tumors, when training a model on multiple tumor types, this variable can also be defined to be equal to 1 if the patient has a history of smoking and the tumor type is lung tumors and zero otherwise.
  • the encoding module 314 represents distribution of expression levels of a particular gene or transcript for each gene or transcript in the human genome as summary statistics (e,g., mean, median) of distribution of expression levels by using reference databases such as TCGA.
  • summary statistics e.g., mean, median
  • TCGA reference databases
  • the encoding module 314 represents mutation type as a length-one one-hot-encoded variable over the alphabet of mutation types (e.g., missense, frameshift, NMD-inducing, etc). These onehot-encoded variables can be included in the allele- nonmteracting variables w l .
  • the encoding module 314 represents protein-level features of protein as the value of the annotation (e.g., 5' UTR length) of the source protein in the allele- noninteracting variables w
  • the encoding module 314 represents residue- level annotations of the source protein for peptide p K by including an indicator variable, that is equal to 1 if peptide p k overlaps with a helix motif and 0 otherwise, or that is equal to I if peptide / is completely contained with within a helix motif in the allele-noninteracting variables w ! .
  • a feature representing proportion of residues in peptide p k that are contained within a helix motif annotation can be included in the allele-noninteracting variables w'.
  • the encoding module 314 represents type of proteins or isoforms in the human proteome as an indicator vector o k that has a length equal to the number of proteins or isoforms in the human proteome, and the corresponding element o h j is 1 if peptide p k comes from protein and 0 otherwise.
  • the encoding module 314 may also represent the overall set of variables z! for peptide p' and an associated MHC allele h as a row vector in which numerical representations of the allele-interacting variables x l and the allele-noninteracting variables w" are
  • the encoding module 314 may represent Z h as a row vector equal to j.v; w l ] or [wi .v;
  • the training module 316 constructs one or more presentation models that generate likelihoods of whether peptide sequences will be presented by MHC alleles associated with the peptide sequences. Specifically, given a peptide sequence p k and a set of MHC alleles a associated with the peptide sequence p k , each presentation model generates an estimate 3 ⁇ 4 indicating a likelihood that the peptide sequence p k will be presented by one or more of the associated MHC alleles a k .
  • the training module 3 6 constructs the one more presentation models based on the training data sets stored in store 170 generated from the presentation information stored in 165.
  • all of the presentation models capture the dependence between independent variables and dependent variables in the training data 170 such that a loss function is minimized.
  • the loss function (y iS s Hies, ⁇ ) represents discrepancies between values of dependent variables y, e s for one or more data instances S in the training data 170 and the estimated likelihoods u, e s for the data instances S generated by the presentation model.
  • the loss function is the mean squared loss given by equation lb as follows:
  • the presentation model may be a parametric model in which one or more parameters ⁇ mathematically specify the dependence between the independent variables and dependent variables.
  • various parameters of parametric-type presentation models that minimize the loss function are determined through gradient-based numerical optimization algorithms, such as batch gradient algorithms, stochastic gradient algorithms, and the like.
  • the presentation model may be a non-parametric model in winch the model structure is determined from, the training data 170 and is not strictly based on a fixed set of parameters.
  • the training module 316 may construct the presentation models to predict presentation likelihoods of peptides on a per-allele basis. In this case, the training module 316 may train the presentation models based on data instances S in the training data 170 generated from cells expressing single MHC alleles.
  • the training module 316 models the estimated presentation likelihood Uk for peptide p k for a specific allele h by:
  • the values for the set of parameters ft for each MHC allele h can be determined by minimizing the loss function with respect to ft, where i is each instance in the subset S of training data 170 generated from cells expressing die single MHC allele h.
  • the output of the dependency function gh(xh ,'0h) represents a dependency score for the MHC allele h indicating whether the MHC allele h will present die corresponding neoantigen based on at least die allele interacting features ⁇ 3 ⁇ 4* and in particular, based on positions of amino acids of the peptide sequence of peptide p K .
  • the dependency score for the MHC allele h may have a high value if the MHC allele h is likely to present the peptide / , and may have a low value if presentation is not likely.
  • the transformation function ⁇ -) transforms the input, and more specifically, transforms the dependency score generated by g;, ⁇ x ;i3 ⁇ 4) in this case, to an appropriate value to indicate the likelihood that the peptide p k will be presented by an MHC allele.
  • J(-) is a function having the range within [0, 1] for an appropriate domain range.
  • ( ⁇ ) is the expit function given by:
  • ( ⁇ ) can also be the hyperbolic tangent function given by:
  • f(z) tanh(z) (5) when the values for the domain z is equal to or greater than 0.
  • f(z) tanh(z) (5) when the values for the domain z is equal to or greater than 0.
  • predictions are made for the mass spectrometry ion current that have values outside the range [0, 1 ],./( ⁇ ) can be any function such as the identity function, the exponential function, the log function, and the like.
  • the per-allele likelihood that a peptide sequence p k will be presented by a MHC allele h can be generated by applying the dependency function g ( ⁇ ) for the MHC allele h to the encoded version of the peptide sequence p k to generate the corresponding dependency score .
  • the dependency score may be transformed by the transformation function ⁇ ) to generate a per-allele like/ihood that the peptide sequence p k will be presented by the 2 allele h.
  • the dependency function # / ,( ⁇ ) is an affine function given by:
  • the dependency function is a network function given by:
  • ⁇ 3 ⁇ 4( ⁇ ) having a series of nodes arranged in one or more layers.
  • a node may be connected to other nodes through connections each having an associated parameter in the set of parameters ⁇ 3 ⁇ 4.
  • a value at one particular node may be represented as a sum of the values of nodes connected to the particular node weighted by the associated parameter mapped by an activation function associated with the particular node.
  • network models are advantageous because the presentation model can incorporate non-linearity and process data having different lengths of amino acid sequences. Specifically, through non-linear modeling, network models can capture interaction between amino acids at different positions in a peptide sequence and how this interaction affects peptide presentation.
  • netw ork models ⁇ 3 ⁇ 4( ⁇ ) may be structured as feed-forward networks, such as artificial neural networks (ANN), convolutional neural networks (CNN), deep neural networks (DNN), and/or recurrent networks, such as long short-term memory networks (LSTM), bi-directional recurrent networks, deep bi-directional recurrent networks, and the like.
  • ANN artificial neural networks
  • CNN convolutional neural networks
  • DNN deep neural networks
  • recurrent networks such as long short-term memory networks (LSTM), bi-directional recurrent networks, deep bi-directional recurrent networks, and the like.
  • each MHC allele in / ⁇ ..?. ... , m is associated with a separate network model
  • Nh ⁇ -) denotes the output(s) from a network model associated with MHC allele h.
  • FIG. 5 illustrates an example network model ⁇ 3 ( ⁇ ) in association with an arbitrary MHC allele /? 3.
  • the network model ⁇ 3 ⁇ ) for MHC allele h - 3 includes three input nodes at layer 1---1, four nodes at layer h- ⁇ - ⁇ 2, two nodes at layer ⁇ -- 3, and one output node at layer / ⁇ /
  • the network model NNj(-) is associated with a set of ten parameters 03( 1), 3 ⁇ 4(2), ... . ⁇ 3 ⁇ 4(10).
  • the identified MHC alleles h --- l, 2 m are associated with a single network model ⁇ ' ⁇ 3 ⁇ 4( ⁇ ), and NN,(-) denotes one or more outputs of the single network model associated with MHC allele h.
  • the set of parameters O h may correspond to a set of parameters for the single ne twork model, and thus, the set of parameters ⁇ 3 ⁇ 4 may be shared by all MHC alleles.
  • the single network model ⁇ ⁇ ⁇ ⁇ ( ⁇ ) may be a network model that outputs a dependency score given the allele interacting variables ⁇ 3 ⁇ 4* and the encoded protein sequence i3 ⁇ 4 of an MHC allele h.
  • the set of parameters ⁇ 3 ⁇ 4 may again correspond to a set of parameters for the single network model, and thus, the set of parameters 3 ⁇ 4 may be shared by all MHC alleles.
  • ⁇ , ⁇ ) may denote the output of the single network model ⁇ ⁇ ( ⁇ ) given inputs jx i/ 3 ⁇ 4 ] to the single network model.
  • Such a network model is advantageous because peptide presentation probabilities for MHC alleles that were unknown in tlie training data can be predicted just by identification of their protein sequence.
  • FIG. 6B illustrates an example network model ⁇ ( ⁇ ) shared by MHC alleles.
  • g ' / ,(.*3 ⁇ 4*;0' / ,) is the affine function with a set of parameters ⁇ , tlie network function, or the like, with a bias parameter ⁇ / , 0 in the set of parameters for allele interacting variables for the MHC allele that represents a baseline probability of presentation for the MHC allele h.
  • the bias parameter ⁇ 3 ⁇ 4° may be shared according to the gene family of the MHC allele h. That is, the bias parameter 3 ⁇ 4° for MHC allele h may be equal to where gene(h) is the gene family of MHC allele h.
  • MHC alleles HLA-A*02:01 , HLA-A* 02:02, and HLA-A*02:03 may be assigned to the gene family of "HLA-A,” and the bias parameter O h for each of these MHC alleles may be shared.
  • the network model NNj(-) receives the ailele-interacting variables x for MHC allele h ---3 and generates the output NNj(j: ).
  • the output is mapped by function ( ⁇ ) to generate the estimated presentation likelihood xik.
  • the training module 316 incorporates allele-nomnteracting variables and models the estimated presentation likelihood iik for peptide p k by:
  • w* denotes the encoded allele-noninteracting variables for peptide p k
  • g w (-) is a function for the allele-noninteracting variables w k based on a set of parameters 0 W determined for the allele-noninteracting variables.
  • the values for the set of parameters ⁇ ⁇ > for each MHC allele h and the set of parameters ⁇ ⁇ . for allele-noninteracting variables can be determined by minimizing the loss function with respect to i3 ⁇ 4 and 0 W , where / ' is each instance in the subset S of training data 170 generated from cells expressing single MHC alleles.
  • the output of the dependency function g w (w k ;fJ w ) represents a dependency score for the allele noninteractmg variables indicating whether the peptide p k will be presented by one or more MHC alleles based on the impact of allele noninteracting variables.
  • the dependency score for the allele noninteracting variables may have a high value if the peptide p k is associated with a C-terminal flanking sequence that is known to positively impact presentation of the peptide / , and may have a low value if the peptide p k is associated with a C-terminal flanking sequence that is known to negatively impact presentation of the peptide p k .
  • the per-aliele likelihood that a peptide sequence p k will be presented by a MHC allele h can be generated by applying the function g h (-) for the MHC allele h to the encoded version of the peptide sequence p k to generate the corresponding dependency score for allele interacting variables.
  • the function g w ⁇ -) for the allele noninteracting variables are also applied to the encoded version of the allele noninteracting variables to generate the dependency score for the allele noninteracting variables. Both scores are combined, and the combined score is transformed by the transformation function /( ⁇ ) to generate a per-allele likelihood that the peptide sequence p k will be presented by the MHC allele h.
  • the training module 316 may include allele-noninteracting variables w k in the prediction by adding the allele-noninteracting variables w K to the allele-interacting variables in equation (2).
  • the dependency function g w 0) for allele noninteracting variables may be an affme function or a network function in which a separate network model is associated with allele-noninteracting variables w k .
  • the dependency function g w (-) is an affine function given by: that linearly combines the allele-noninteracting variables in w k with a corresponding parameter in the set of parameters 0 W .
  • the dependency function g w (-) may also be a network function given by:
  • g k (w k ; O w ) NN w (w k ; e w ).
  • NN W (-) having an associated parameter in the set of parameters 0 W .
  • g w k e w g ! w ⁇ w k 0 ! w ) + h(m k ; ⁇ ), (10)
  • g is the affine function, the network function with the set of allele noninteracting parameters 0 v , or the like
  • w is the mRMA quantification measurement for peptide p k
  • h(-) is a flinction transforming the quantification measurement
  • ⁇ - " is a parameter in the set of parameters for allele noninteracting variables that is combined with the mRNA quantification measurement to generate a dependency score for tlie mRMA quantification measurement.
  • /?( ⁇ ) is the log function, however in practice /?( ⁇ ) may be any one of a variety of different functions.
  • the dependency function the dependency function g n ⁇ -) for the allele-noninteracting variables can be given by:
  • a parameter regulars zation term such as ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ , where j j ⁇ j j represents LI norm, L2 norm, a combination, or the like, can be added to the loss function when determining the value of the parameters.
  • the optimal value of the hyperparameter ⁇ can be determined through appropriate methods.
  • the likelihood that peptide p k will be presented by MHC allele h 3. among m---4 different identified MHC alleles using the affine transformation functions g h (; ⁇ , gw('), can be generated by:
  • w K are the identified allele-noninteracting variables for peptide p k
  • 0 W are the set of parameters determined for the allele-noninteracting variables.
  • the network model NN;(-) receives the allele-interacting variables x for MHC allele /? 3 and generates the
  • the network model NN W (-) receives the allele- noninteracting variables w k for peptide p k and generates the output NN w (w k ).
  • the outputs are combined and mapped by function _/( ⁇ ) to generate the estimated presentation likelihood U' .
  • the training module 316 may also construct the presentation models to predict presentation likelihoods of peptides in a multiple-allele setting where two or more MHC alleles are present. In this case, the training module 316 may train the presentation models based on data instances S in the training data 170 generated from, cells expressing single MHC alleles, cells expressing multiple MHC alleles, or a combination thereof.
  • the training module 316 models the estimated presentation likelihood Uk for peptide p k in association with a set of multiple MHC alleles H as a function of the presentation likelihoods u ⁇ ' eM determined for each of the MHC alleles h in the set H determined based on cells expressing singie-alleles, as described above in conjunction with equations (2)-(l 1).
  • the presentation likelihood iiu can be any function of Uk eH .
  • the function is the maximum function, and the presentation likelihood iik can be determined as the maximum of the presentation likelihoods for each MHC allele h in the set H.
  • the training module 316 models the estimated presentation likelihood ii for peptide p k by; u k - Pr(p fc presented) - (13)
  • the values for the set of parameters for each MHC allele h can be determined by minimizing the loss function with respect to 3 ⁇ 4, where i is each instance in the subset S of training data 170 generated from cells expressing single MHC alleles and/or cells expressing multiple MHC alleles.
  • the dependency function gi may be in the form of any of the dependency functions gu introduced above in sections ⁇ 111 B ! .
  • the presentation likelihood that a peptide sequence p k will be presented by one or more MHC alleles h can be generated by applying the dependency function gh ⁇ -) to the encoded version of the peptide sequence p k for each of the MHC alleles Hto generate the corresponding score for the allele interacting variables.
  • the scores for each MHC allele h are combined, and transformed by the transformation function /( ⁇ ) to generate the presentation likelihood that peptide sequence p k will be presented by the set of MHC alleles H.
  • the presentation model of equation (13) is different from the per-allele model of equation (2), in that the number of associated alleles for each peptide p k can be greater than 1. In other words, more than one element in a h k can have values of 1 for the multiple MHC alleles H associated with peptide sequence p K .
  • u k f(NN 2 0 2 ) + NN 3 (x k 3 ; ⁇ 3 )),
  • the network model NN ? (-) receives the allele-interacting variables x for MHC allele /: ⁇ 2 and generates the output
  • the network model N V3 ⁇ 4(-) receives the allele- interacting variables x for MHC allele h 3 and generates the output NA'j(x ).
  • the outputs are combined and mapped by function /( ⁇ ) to generate the estimated presentation likelihood
  • the training module 316 incorporates allele-noninteracting variables and models the estimated presentation likelihood tik for peptide p k by: u k - Pr(p k presented) - 4 ⁇ g h ⁇ x k k ;. 0 h ) V (14)
  • the presentation likelihood that a peptide sequence p k will be presented by one or more MHC alleles H can be generated by applying the function g3 ⁇ 4(-) to the encoded version of the peptide sequence p k for each of the MHC alleles H to generate the corresponding dependency score for allele interacting variables for each MHC allele h.
  • the function g w (-) for the allele noninteracting variables is also applied to the encoded version of the allele noninteracting variables to generate the dependency score for the allele noninteracting variables.
  • the scores are combined, and the combined score is transformed by the transformation function /( ⁇ ) to generate the presentation likelihood that peptide sequence p k will be presented by the MHC alleles H.
  • the number of associated alleles for each peptide p k can be greater than 1.
  • more than one element in a, h can have values of 1 for the multiple MHC alleles / associated with peptide sequence / .
  • w k are the identified allele-noninteracting variables for peptide p k
  • 0 W are the set of parameters determined for the allele-noninteracting variables.
  • u k f(NN w ⁇ w k ; 0 W ) + NN 2 (x k ; 0 2 ) + NN 3 (x k 3 ; 0 3 ))
  • w k are the identified ailele-interacting variables for peptide p k
  • 0 W are the set of parameters determined for allele-noninteracting variables.
  • the network model ⁇ ⁇ ( ⁇ ) receives the allele-noninteracting variables w k for peptide p k and generates the output NN w (w*). The outputs are combined and mapped by function ⁇ ⁇ ) to generate the estimated presentation likelihood 3 ⁇ 43 ⁇ 4.
  • the training module 316 may include allele-noninteracting variables w k in the prediction by adding the allele-noninteracting variables w k to the ailele-interacting variables ⁇ 3 ⁇ 4* in equation (15).
  • the presentation likelihood can be given by: u k - Pr(p k presented) - ⁇ 9h ([x w k ]; e h )j . (15) VIII.C.4.
  • Example 3.1 Models Using Implicit Per- Allele
  • the training module 316 models the estimated presentation likelihood 3 ⁇ 4 for peptide p K by:
  • s ⁇ -) may be the summation function or the second-order function, but it is appreciated that in other embodiments, .?( ⁇ ) can be any function such as the maximum function.
  • Tire values for the set of parameters 0 for the implicit per-allele likelihoods can be determined by minimizing the loss function with respect to ⁇ , where is each instance in the subset S of training data 170 generated from, cells expressing single MHC alleles and/or cells expressing multiple MHC alleles,
  • the presentation likelihood in the presentation model of equation (17) is modeled as a function of implicit per-allele presentation likelihoods u V that each correspond to the likelihood peptide p" will be presented by an individual MHC allele h.
  • the implicit per-allele likelihood is distinct from the per-allele presentation likelihood of section VTII.B in that the parameters for implicit per-allele likelihoods can be learned from multiple allele settings, in which direct association between a presented peptide and the corresponding MHC allele is unknown, in addition to single-allele settings.
  • the presentation model can estimate not only whether peptide p k will be presented by a set of MHC alleles H as a whole, but can also provide individual likelihoods u ' ⁇ ' ⁇ ' ⁇ that indicate which MHC allele h most likely presented peptide p k .
  • An advantage of this is that the presentation model can generate the implicit likelihoods without training data for cells expressing single MHC alleles.
  • r(-) is a function having the range [0, 1 ] .
  • r(-) may be the clip function:
  • s(-) is a summation function, and the presentation likelihood is given by summing the implicit per-allele presentation likelihoods:
  • the implicit per-allele presentation likelihood for MHC allele h is generated by:
  • the presentation likelihood that a peptide sequence p k will be presented by one or more MHC alleles H can be generated by applying the function gh(-) to the encoded version of the peptide sequence p k for each of the MHC alleles Hto generate the corresponding dependency score for allele interacting variables.
  • Each dependency score is first transformed by the function ( ⁇ ) to generate implicit per-allele presentation likelihoods u
  • the per-allele likelihoods u are combined, and the clipping function may be applied to the combined likelihoods to clip the values into a range [0, 1 ] to generate the presentation likelihood that peptide sequence p k will be presented by the set of MHC alleles H.
  • the dependency function gu may be in the form of any of the dependency functions gu introduced above in sections VIII. B, 1.
  • the likelihood that peptide p k will be presented by MHC alleles h 2. !i 3. among -l different identified MHC alleles using the affine transformation functions gk ⁇ '), can be generated by:
  • the likelihood that peptide p k will be presented by MHC alleles h ---2, h ⁇ 3, among m ---4 different identified MHC alleles using the network transformation functions £ ⁇ 4( ⁇ , gw(:), can be generated by:
  • Each output is mapped by function and combined to generate the estimated presentation likelihood 3 ⁇ 4,
  • r(-) is the log function and /( ⁇ ) is the exponential function.
  • the implicit per-ailele presentation likelihood for MHC allele h is generated by:
  • uk ' h f (an ( x h ®k) + 9w ( ⁇ fc ; o w ) , (20 ) such that the presentation likelihood is generated by:
  • the presentation likelihood that a peptide sequence p k will be presented by one or more MHC alleles H can be generated by applying the function gh ⁇ ) to the encoded version of the peptide sequence p k for each of the MHC alleles Hto generate the corresponding dependency score for allele interacting variables for each MHC allele h.
  • the function g w (-) for the allele noninteracting variables is also applied to the encoded version of the allele noninteracting variables to generate the dependency score for the allele noninteracting variables.
  • the score for the allele noninteracting variables are combined to each of the dependency scores for the allele interacting variables.
  • Each of the combined scores are transformed by the function ( ⁇ ) to generate the implicit per-allele presentation likelihoods.
  • the implicit likelihoods are combined, and the clipping function may be applied to the combined outputs to clip the values into a range [0,1] to generate the presentation likelihood that peptide sequence p k will be presented by the MHC alleles H.
  • the dependency function g w may be in the form of any of the dependency functions # w introduced above in sections V1II.B.3.
  • the likelihood that peptide p k will be presented by MHC alleles h 2. !i 3. among -I different identified MHC alleles using the affine transformation functions gh ⁇ '), g ), can be generated by:
  • w k are the identified allele-noninteracting variables for peptide p k
  • ⁇ are the set of parameters determ ined for the allele-noninteracting variables.
  • the likelihood that peptide p k will be presented by MHC alleles h 2. 3. among -i different identified MHC alleles using the network transformation functions gh( ), g-A;), can be generated by:
  • u k r (f (NN w (w k ; 0 abuse,) + NN 2 (x k 2 ; 0 2 )) + f ⁇ NN w (w k ; 0 W ) + NN 3 (x k ; 0 3 )))
  • w* are the identified allele-interacting variables for peptide p k
  • 0 W are the set of parameters determined for allele-noninteracting variables.
  • FIG. 12 illustrates generating a presentation likelihood for peptide p k in association with MHC alleles h ----2. h -- 3 using example network models NN£), AWj(-), and NN W (- ⁇ .
  • the network model NNw(-) receives the allele-noninteracting variables w k for peptide p k and generates the output NN w (w*).
  • the outputs are combined and mapped by function /( ⁇ ).
  • the implicit per-allele presentation likelihood for MHC allele h is generated by:
  • .?( ⁇ ) is a second-order function
  • the estimated presentation likelihood iik for peptide p k is given by:
  • elements u c h are the implicit per-allele presentation likelihood for MHC allele h.
  • the values for the set of parameters 0 for the implicit per-allele likelihoods can be determined by- minimizing the loss function with respect to ⁇ , where is each instance in the subset S of training data 170 generated from cells expressing single MHC alleles and/or cells expressing multiple MHC alleles.
  • the implicit per-allele presentation likelihoods may be in any form shown in equations (18), (20), and (22) described above.
  • the model of equation (23) may imply that there exists a possibility peptide p K will be presented by two MHC alleles simultaneously, in which the presentation by two HLA alleles is statistically independent.
  • the presentation likelihood that a peptide sequence p k will be presented by one or more MHC alleles H can be generated by combining the implicit per-allele presentation likelihoods and subtracting the likelihood that each pair of MHC alleles will simultaneously present the peptide from the summation to generate the presentation likelihood that peptide sequence p k will be presented by the MHC alleles H.
  • u k (** ⁇ ⁇ ,) + ( ⁇ e 3 ) - / ' ( ! ⁇ ⁇ 2 ) ⁇ / ⁇ (*! ⁇ ⁇ 3 ),
  • the prediction module 320 receives sequence data and selects candidate neoantigens in the sequence data using the presentation models. Specifscally, the sequence data may be DNA sequences, RNA sequences, and/or protein sequences extracted from tumor tissue cells of patients. The prediction module 320 processes the sequence data into a plurality of peptide sequences p k having 8-15 amino acids.
  • the prediction module 320 may process the given sequence "IEFROEIFJEF into three peptide sequences having 9 ammo acids "IEFROEIFJ,” “EFROEIFJE,” and "FROEIFJEF.” In one embodiment, the prediction module 320 may identify candidate neoantigens that are mutated peptide sequences by comparing sequence data extracted from normal tissue cells of a patient with the sequence data extracted from tumor tissue cells of the patient to identify portions containing one or more mutations.
  • the presentation module 320 applies one or more of the presentation models to the processed peptide sequences to estimate presentation likelihoods of the peptide sequences.
  • the prediction module 320 may select one or more candidate neoantigen peptide sequences that are likely to be presented on tumor HLA molecules by applying the presentation models to the candidate neoantigens.
  • the presentation module 320 selects candidate neoantigen sequences that have estimated presentation likelihoods above a predetermined threshold.
  • the presentation model selects the N candidate neoantigen sequences that have the highest estimated presentation likelihoods (where Nis generally the maximum number of epitopes that can be delivered in a vaccine).
  • a vaccine including the selected candidate neoantigens for a given patient can be injected into the patient to induce immune responses.
  • AUC area-under-curve
  • FIG. 13A compares performance results of an example presentation model, as presented herein, and state-of-the-art models for predicting peptide presentation on multiple- allele mass spectrometiy data. Results showed that the example presentation model performed significantly better at predicting peptide presentation than state-of-the-art models based on affinity and stability predictions.
  • the example presentation model shown in FIG. 13A as "MS” was the maximum of per-aileles presentation model shown in equation (12), using the affine dependency function g,3 ⁇ 4(-) and the expit function /( ⁇ ).
  • the example presentation model was trained based on a subset of the single-allele HLA-A*02:01 mass spectrometiy data from the 1EDB data set (data set "Dl”) (data can be found at
  • the example presentation model trained on mass spectrometry data had a significantly higher PPV value at 0% recall rate relative to the state-of-the-art models that predict peptide presentation based on MHC binding affinity predictions or MHC binding stability predictions.
  • the example presentation model had approximately 14% higher PPV than the model based on affinity predictions, and had approximately 12% higher PPV than the model based on stability predictions.
  • FIG. 13B compares performance results of another example presentation model, as presented herein, and state-of-the-art models for predicting peptide presentation on T-cell epitope data.
  • T-cell epitope data contains peptide sequences that were presented by MHC alleles on the cell surface, and recognized by T-cells. Results showed that even though the example presentation model is trained based on mass spectrometry data, the example presentation model performed significantly better at predicting T-cell epitopes than state-of- the-art models based on affinity and stability predictions. In other words, the results of FIG .
  • the example presentation model shown in FIG. 13B as "MS" was the per-allele presentation model shown in equation (2), using the affine transformation function £ / ,( ⁇ ) and the expit function /( ⁇ ) that was trained based on a subset of data set Dl . All peptides from source protein that contain presented peptides in the test set were eliminated from the training data such that the presentation model could not simply memorize the sequences of presented antigens.
  • the per-allele presentation model trained on mass spectrometiy data had a significantly higher PPV value at 10% recall rate than the state- of-the-art models that predict peptide presentation based on MHC binding affinity or MHC binding stability predictions even though the presentation model was not trained based on protein sequences that contained presented peptides.
  • the per-allele presentation model had approximately 9% higher PPV than the model based on affinity predictions, and had approximately 8% higher PPV than the model based on stability predictions.
  • FIG. 13C compares performance results for an example function-of-sums model (equation (13)), an example sum-of-functions model (equation (1 )), and a example second order model (equation (23)) for predicting peptide presentation on muitiple-allele mass spectrometry data. Results showed that the sum-of-functions model and second order model performed better than the function-of-sums model. This is because the function-of-sums model implies that alleles in a muitiple-allele setting can interfere with each other for peptide presentation, when in reality, the presentation of peptides are effectively independent.
  • the example presentation model labeled as "sigmoid-of-sums” in FIG. -13C was the function-of-sums model using a network dependency function gh(- ⁇ , the identity function /( ⁇ ), and the expit function r(-).
  • the example model labeled as "sum-of- sigmoids" was the sum-of-functions model in equation ( 19) with a network dependency function g / ,(-), the expit function /( ⁇ ), and the identity function / ⁇ ( ⁇ ).
  • the example model labeled as "hyperbolic tangent” was the sum-of-functions model in equation (19) with a network dependency function g3 ⁇ 4Q, the expit function ft-), and the hyperbolic tangent function r(-).
  • the example model labeled as "second order " ' was the second order model in equation (23) using an implicit per-allele presentation likelihood form shown in equation (18) with a network dependency function g h ⁇ -) and the expit function /( ⁇ ).
  • Each model was trained based on a subset of data set D l, D2, and D3.
  • the example presentation models were applied to a test data that is a random subset of data set D3 that did not overlap with the training data.
  • the first colum refers to the AUC of the ROC when each presentation model was applied to the test set
  • the second column refers to the value of the negative log likelihood loss
  • the third column refers to the PPV at 10% recall rate.
  • the performance of presentation models "sum-of-sigmoids,” “hyperbolic tangent,” and “second order” were approximately tied at approximately 15- 16% PPV at 10% recall, while the performance of the model “sigmoid-of-sums" was slightly lower at approximately 1 1%.
  • FIG. 13D compares performance results for two example presentation models that are trained with and without singie-allele mass spectrometry data on predicting peptide presentation for multiple-allele mass spectrometry data. The results indicated that example presentation models that are trained without singie-allele data achieve comparable performance to that of example presentation models trained with singie-allele data,
  • the example model "with A2 B7 singie-allele data” was the "sum-of-sigmoids" presentation model in equation (19) with a network dependency function g ('), the expit function ( ⁇ ), and the identity function r(-).
  • the model was trained based on a subset of data set D3 and singie-allele mass spectrometr ⁇ ' data for a variety of MHC alleles from the IEDB database (data can be found at: http://www.iedb.org/doc/mhc_ligand_full.zip).
  • the example model "without A2/B7 singie-allele data" was the same model, but trained based on a subset of the multiple-allele D3 data set without singie-allele mass spectrometry data for alleles HLA-A*02:01 and HLA-B*07:02, but with singie-allele mass spectrometr ⁇ ' data for other alleles.
  • cell line HCC1937 expressed HLA-B*07:02 but not HLA-A* 02:01
  • cell line HCT116 expressed HLA-A*02:01 but not HLA- B*07:02.
  • the example presentation models were applied to a test data that was a random subset of data set D3 and did not overlap with the training data.
  • the column “Correlation” refers to the correlation between the actual labels that indicate whether the peptide was presented on the corresponding allele in the test data, and the label for prediction.
  • the predictions based on the implicit per- allele presentation likelihoods for MHC allele HLA-A*02:01 performed significantly better on singie-allele test data for MHC allele HLA-A*02:01 rather than for MHC allele HLA- B*07:02, Similar results are shown for MHC allele HLA-B*07:02.
  • FIG. I3E shows performance for the "without A2/B7 singie-allele data" and "with A2/B7 singie-allele data" example models shown in FIG. 13D on singie-allele mass spectrometry data for alleles HLA-A*02:01 and HLA-B*07:02 that were held out in the analysis shown in FIG. 13D.
  • Results indicate that even through the example presentation model is trained without single-allele mass spectrometry data for these two alleles, the model is able to learn binding motifs for each MHC allele,
  • A2 model predicting B7 indicates the performance of the model when peptide presentation is predicted for single-allele HLA-B*07:02 data based on the implicit per-allele presentation likelihood estimate for MHC allele HLA-A*02:01.
  • A2 model predicting A2 indicates the performance of the model when peptide presentation is predicted for single-allele HLA-A*02:01 based on the implicit per-allele presentation likelihood estimate for MHC allele HLA-A*02:01.
  • B7 model predicting B7 indicates the performance of the model when peptide presentation is predicted for single- allele HLA-B*07:02 data based on the implicit per-allele presentation likelihood estimate for MHC allele HLA-B* 07:02.
  • B7 model predicting A2 indicates the performance of the model when peptide presentation is predicted for single-allele HLA ⁇ A*02:01 based on the implicit per-allele presentation likelihood estimate for MHC allele HLA-B*07:02.
  • FIG. I3F shows the common anchor residues at positions 2 and 9 among nonamers predicted by the "without A2/B7 single-allele data" example model shown in FIG. 13D.
  • the peptides were predicted to be presented if the estimated likelihood was above 5%.
  • Results show that most common anchor residues in the peptides identified for presentation on the MHC alleles HLA-A*02:01 and HLA-B* 07: 02 matched previously known anchor motifs for these MHC alleles. This indicates that the example presentation models correctly learned peptide binding based on particular positions of amino acids of the peptide sequences, as expected.
  • amino acids L/M at position 2 and amino acids V/L at position 9 were known to be canonical anchor residue motifs (as shown in Table 4 of https://link.springer.com/article/10.1 186/1745-7580-4-2) for HLA-A* 02:01, and amino acid P at position 2 and amino acids L/V at position 9 were known to be canonical anchor residue motifs for HLA-B*07:02.
  • the most common anchor residue motifs at positions 2 and 9 for peptides identified the model matched the known canonical anchor residue motifs for both HLA alleles.
  • FIG. 13G compares performance results between an example presentation model that incorporated C- and -terminal flanking sequences as aliele-interacting variables, and an example presentation model that incorporated C- and N-terminal flanking sequences as allele-noninteracting variables. Results showed that incorporating C- and N-terminal flanking sequences as allele noninteracting variables significantly improved model performance. More specifically, it is valuable to identify appropriate features for peptide presentation that are common across different MHC alleles, and model them such that statistical strength for these allele-noninteracting variables are shared across MHC alleles to improve presentation model performance.
  • the example '"aliele-interacting” model was the sum-of-functions model using the form of implicit per-allele presentation likelihoods in equation (22) that incorporated C- and N-terminal flanking sequences as aliele-interacting variables, with a network dependency function » / ,( ⁇ ) and the expit function /( ⁇ ).
  • the example "allele-noninteracting" model was the sum-of-functions model shown in equation (21) that incorporated C ⁇ and N-terminal flanking sequences as allele-noninteracting variables, with a network dependency function g3 ⁇ 4(-) and the expit function /( ⁇ ).
  • the allele-noninteracting variables were modeled through a separate network dependency function g w (-).
  • Both models were trained on a subset of data set D3 and single-allele mass spectrometry data for a variety of MHC alleles from the IEDB database (data can be found at: http://www.iedb.org/doc/mhc_ligand_full.zip).
  • Each of the presentation models was applied to a test data set that is a random subset of data set D3 that did not overlap with the training data.
  • FIG. 13H illustrates the dependency between fraction of presented peptides for genes based on mRNA quantification for mass spectrometry data on tumor cells. Results show that there is a strong dependency between mRNA expression and peptide presentation.
  • the horizontal axis in FIG.13G indicates mRNA expression in terms of transcripts per million (TPM) quartiles.
  • the vertical axis in FIG. 13G indicates fraction of presented epitopes from genes in corresponding mRNA expression quartiles.
  • Each solid line is a plot relating the two measurements from a tumor sample that is associated with corresponding mass spectrometry data and mRNA expression measurements.
  • FIG. 13G there is a strong positive correlation between mRNA expression, and the fraction of peptides in the corresponding gene.
  • peptides from genes in the top quartile of RNA expression are more than 20 times likely to be presented than the bottom quartile.
  • FIG. 131 shows performance of two example presentation models, one of which is trained based on mass spectrometry tumor cell data, another of which incorporates mRNA quantification data and mass spectrometry tumor cell data.
  • MHC flurry + RNA filter was a model similar to the current state-of-the-art model that predicts peptide presentation based on affinity predictions. It was implemented using MHCflurry along with a standard gene expression filter that removed all peptides from proteins with mRNA quantification measurements that were less than 3.2 FPKM.
  • Example Model, no RNA model was the "sum-of-sigmoids" example presentation model shown in equation (21) with the network dependency function ⁇ 3 ⁇ 4( ⁇ ), the network dependency function gv(-), and the expit function ( ⁇ ).
  • the '"Example Model, no RNA” model incorporated C-terminal flanking sequences as allele-noninteracting variables through a network dependency function g w (- ⁇ ,
  • the ''Example Model, with RNA” model was the "sum-of-sigmoids" presentation model shown in equation (19) with network dependency function gh( ), the network dependency function g w (-) in equation (10) incorporating mRNA quantification data through a log function, and the expit function ( ⁇ ).
  • the "Example Model, with RNA” model incorporated C-terminal flanking sequences as allele-noninteracting variables through the network dependency functions g w (-) and incorporated mRNA quantification measurements through the log function.
  • Each model was trained on a combination of the single-allele mass spectrometry data from the 1EDB data set, 7 ceil lines from the multiple-alleie mass spectrometry data from the Bassani-Sternberg data set, and 20 mass spectrometry tumor samples. Each model was applied to a test set including 5,000 held-out proteins from 7 tumor samples that constituted 9,830 presented peptides from a total of 52, 156,840 peptides.
  • the "Example Model, no RNA” model has a PPV value at 20% Recall of 21%, while that of the state-of-the-art model is approximately 3%, This indicates an initial performance improvement of 18% in PPV value, even without the incorporation of mRNA quantification measurements.
  • the "Example Model, with RNA " model that incorporates mRN A quantification data into the presentation model shows a PPV value of approximately 30%, which is almost a 10% increase in performance compared to the example presentation model without mRNA quantification measurements.
  • FIG. 131 compares probability of peptide presentation for different peptide lengths between results generated by the "Example Model, with RNA” presentation model described in reference to FIG. 131, and predicted results by state-of-the-art models that do not account for peptide length when predicting peptide presentation. Results indicated that the "Example Model, with RNA” example presentation model from FIG. 131 captured variation in likelihoods across peptides of differing lengths.
  • Tl e vertical axis denoted the probability of peptide presentation conditioned on the lengths of the peptide.
  • the plot "Actual Test Data Probability" showed the proportion of presented peptides according to the length of the peptide in a sample test data set.
  • the presentation likelihood varied with the length of the peptide. For example, as shown in FIG. 13 , a lOmer peptide with canonical HLA-A2 L/V anchor motifs was approximately 3 times less likely to be presented than a 9mer with the same anchor residues.
  • Models Ignoring Length' 1 indicated predicted measurements if state-of-the-art models that ignore peptide length were to be applied to the same test data set for presentation prediction. These models may be NetMHC versions before version 4.0, NetMHCpan versions before version 3.0, and
  • relu(-) is the rectified linear unit (RELU) function
  • W h ! b h , W/, 2 , and b h are the set of parameters ⁇ determined for tlie model .
  • the allele interacting variables x consist of peptide sequences.
  • the dimensions of W h are (231 x 256), tlie dimensions of b h (1 x 256), the dimensions of W)i are (256 x 1), and b h is a scalar.
  • values for b h , b h W h , and W h 2 are listed below.
  • FIG. 14 illustrates an example computer 1400 for implementing the entities shown in FIGS. 1 and 3.
  • the computer 1400 includes at least one processor 1402 coupled to a chipset 1404.
  • the chipset 1404 includes a memory controller hub 1420 and an input/output (I/O) controller hub 1422.
  • a memory 1406 and a graphics adapter 14 2 are coupled to the memory controller hub 1420, and a display 1418 is coupled to the graphics adapter 1412.
  • a storage device 1408, an input device 1414, and network adapter 1416 are coupled to the I/O controller hub 1422.
  • Other embodiments of the computer 1400 have different architectures.
  • the storage device 1408 is a non-transitory computer-readable storage medium such as a hard drive, compact disk read-only memory (CD-ROM), DVD, or a solid-state memory device.
  • the memory 1406 holds instructions and data used by the processor 1402.
  • the input interface 1414 is a touch-screen interface, a mouse, track ball, or other type of pointing device, a keyboard, or some combination thereof, and is used to input data into the computer 1400.
  • the computer 1400 may be configured to receive input (e.g., commands) from the input interface 1414 via gestures from the user.
  • the graphics adapter 1412 displays images and other information on the display 1418.
  • the network adapter 1416 couples the computer 1400 to one or more computer networks.
  • the computer 1400 is adapted to execute computer program modules for providing functionality described herein.
  • module refers to computer program logic used to provide the specified functionality.
  • a module can be implemented in hardware, firmware, and/or software.
  • program modules are stored on the storage device 1408, loaded into the memory 1406, and executed by the processor 1402,
  • the types of computers 1400 used by the entities of FIG . 1 can vary depending upon the embodiment and the processing power required by the entity.
  • the presentation identification system 160 can run in a single computer 1400 or multiple computers 1400 communicating with each other through a network such as in a server farm.
  • the computers 1400 can lack some of the components described above, such as graphics adapters 1412, and displays 1418.
  • Bodini, M. et al. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Biood 125, 600-605 (2015).
  • RNA CoMPASS a dual approach for pathogen and host transcriptome analysis of RNA-seq datasets. PloS One 9, e89445 (2014).
  • HLA -DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells. Br J Haematol. 1982 Nov;52(3):411 -20.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)

Abstract

L'invention concerne un système et des procédés pour déterminer les allèles, les néoantigènes et une composition de vaccin tels que déterminés sur la base de mutations tumorales d'un individu. L'invention concerne également des systèmes et des procédés permettant d'obtenir des données de séquençage de grande qualité à partir d'une tumeur. En outre, la présente invention concerne des systèmes et des procédés pour identifier des changements somatiques dans les données génomiques polymorphiques. L'invention concerne enfin des vaccins anticancéreux uniques.
PCT/US2016/067159 2015-12-16 2016-12-16 Identification de néogènes, fabrication et utilisation WO2017106638A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IL259931A IL259931B2 (en) 2015-12-16 2016-12-16 Identification of neo-antigens, preparation, and use
CA3008641A CA3008641A1 (fr) 2015-12-16 2016-12-16 Identification de neogenes, fabrication et utilisation
AU2016369519A AU2016369519B2 (en) 2015-12-16 2016-12-16 Neoantigen identification, manufacture, and use
JP2018550664A JP7114477B2 (ja) 2015-12-16 2016-12-16 新生抗原の特定、製造、および使用
ES16876766T ES2970865T3 (es) 2015-12-16 2016-12-16 Identificación, fabricación y uso de neoantígenos
RU2018124997A RU2729116C2 (ru) 2015-12-16 2016-12-16 Идентификация, производство и применение неоантигенов
EP23207311.4A EP4299136A3 (fr) 2015-12-16 2016-12-16 Identification de néogènes, fabrication et utilisation
SG11201804957VA SG11201804957VA (en) 2015-12-16 2016-12-16 Neoantigen identification, manufacture, and use
MX2018007204A MX2018007204A (es) 2015-12-16 2016-12-16 Identificacion, fabricacion y uso de neoantigeno.
CN201680080924.4A CN108601731A (zh) 2015-12-16 2016-12-16 新抗原的鉴别、制造及使用
EP16876766.3A EP3389630B1 (fr) 2015-12-16 2016-12-16 Identification de néogènes, fabrication et utilisation
IL305238A IL305238A (en) 2015-12-16 2016-12-16 Identification of neoantigens, preparation, and use
BR112018012374-9A BR112018012374A2 (pt) 2015-12-16 2016-12-16 identificação, fabricação e uso de neoantígeno
KR1020187020164A KR20180107102A (ko) 2015-12-16 2016-12-16 신생항원 동정, 제조, 및 용도
PH12018501267A PH12018501267A1 (en) 2015-12-16 2018-06-13 Neoantigen identification, manufacture, and use
CONC2018/0007417A CO2018007417A2 (es) 2015-12-16 2018-07-13 Identificación, fabricación y uso de neoantígeno
HK19100224.7A HK1257865A1 (zh) 2015-12-16 2019-01-07 新抗原的鑒別、製造及使用
JP2022089465A JP2022133271A (ja) 2015-12-16 2022-06-01 新生抗原の特定、製造、および使用
AU2023204618A AU2023204618A1 (en) 2015-12-16 2023-07-12 Neoantigen identification, manufacture, and use

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562268333P 2015-12-16 2015-12-16
US62/268,333 2015-12-16
US201662317823P 2016-04-04 2016-04-04
US62/317,823 2016-04-04
US201662379986P 2016-08-26 2016-08-26
US62/379,986 2016-08-26
US201662394074P 2016-09-13 2016-09-13
US62/394,074 2016-09-13
US201662425995P 2016-11-23 2016-11-23
US62/425,995 2016-11-23

Publications (1)

Publication Number Publication Date
WO2017106638A1 true WO2017106638A1 (fr) 2017-06-22

Family

ID=59057557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/067159 WO2017106638A1 (fr) 2015-12-16 2016-12-16 Identification de néogènes, fabrication et utilisation

Country Status (19)

Country Link
US (7) US20170199961A1 (fr)
EP (2) EP4299136A3 (fr)
JP (2) JP7114477B2 (fr)
KR (1) KR20180107102A (fr)
CN (1) CN108601731A (fr)
AU (2) AU2016369519B2 (fr)
BR (1) BR112018012374A2 (fr)
CA (1) CA3008641A1 (fr)
CO (1) CO2018007417A2 (fr)
ES (1) ES2970865T3 (fr)
HK (1) HK1257865A1 (fr)
IL (2) IL305238A (fr)
MX (2) MX2018007204A (fr)
PE (1) PE20181535A1 (fr)
PH (1) PH12018501267A1 (fr)
RU (1) RU2729116C2 (fr)
SG (1) SG11201804957VA (fr)
TW (1) TWI765875B (fr)
WO (1) WO2017106638A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136664A1 (fr) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Néoantigènes et leurs utilisations dans le traitement du cancer
WO2018195357A1 (fr) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Identification de néoantigènes, fabrication et utilisation
WO2019006022A1 (fr) * 2017-06-27 2019-01-03 The Broad Institute, Inc. Systèmes et procédés de prédiction d'épitope du cmh de classe ii
WO2019012296A1 (fr) * 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analyse d'allèles hla dans des tumeurs et utilisations associées
JP2019030275A (ja) * 2017-08-09 2019-02-28 学校法人日本大学 口臭判定装置及びプログラム
WO2019075112A1 (fr) * 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Identification de néo-antigènes au moyen de points chauds
CN109682978A (zh) * 2017-11-30 2019-04-26 丁平 一种肿瘤突变肽mhc亲和力预测方法及其应用
WO2020022897A1 (fr) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Procédé de préparation de compositions immunogènes spécifiques à un sujet en s'appuyant sur une base de données de néo-peptides à cadre ouvert de lecture
WO2020072700A1 (fr) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
JP2020071166A (ja) * 2018-11-01 2020-05-07 浜松ホトニクス株式会社 スペクトル分析装置およびスペクトル分析方法
WO2020099614A1 (fr) * 2018-11-15 2020-05-22 Nouscom Ag Sélection de mutations de cancer pour la génération d'un vaccin personnalisé contre le cancer
WO2020141207A1 (fr) 2019-01-03 2020-07-09 Evaxion Biotech Aps Vaccins ciblant des néo-épitopes
WO2020157760A1 (fr) * 2019-01-31 2020-08-06 Bar Ilan University Néo-antigènes créés par épissage aberrant induit et leurs utilisations dans l'amélioration de l'immunothérapie
WO2020182901A1 (fr) 2019-03-11 2020-09-17 Evaxion Biotech Aps Vaccination par acides nucléiques au moyen de constructions de codage de néoépitopes
CN111727262A (zh) * 2017-07-25 2020-09-29 加州理工学院 胞啃介导的表位发现
US10847252B2 (en) 2015-12-16 2020-11-24 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN112368386A (zh) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
JP2021503897A (ja) * 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
WO2021048400A1 (fr) 2019-09-13 2021-03-18 Evaxion Biotech Aps Procédé d'identification d'épitopes de lymphocytes t
WO2021123232A1 (fr) 2019-12-18 2021-06-24 Evaxion Biotech Aps Vaccination par acides nucléiques au moyen de constructions codant pour des néo-épitopes
WO2021204911A1 (fr) 2020-04-07 2021-10-14 Evaxion Biotech A/S Immunothérapie par néo-épitope avec unité de ciblage apc
US11156617B2 (en) 2015-02-12 2021-10-26 BioNTech RNA Pharmaceuticals GbmH Predicting T cell epitopes useful for vaccination
US11222711B2 (en) 2013-05-10 2022-01-11 BioNTech SE Predicting immunogenicity of T cell epitopes
WO2022013277A1 (fr) 2020-07-14 2022-01-20 Evaxion Biotech A/S Unités de ciblage de cpa pour immunothérapie
WO2022013154A1 (fr) 2020-07-14 2022-01-20 Myneo Nv Procédé, système et produit de programme d'ordinateur permettant de déterminer des probabilités de présentation de néoantigènes
CN114340661A (zh) * 2019-07-02 2022-04-12 磨石生物公司 Hiv抗原和mhc复合物
WO2022098936A1 (fr) * 2020-11-06 2022-05-12 Amazon Technologies, Inc. Sélection de néo-antigènes pour un vaccin anticancéreux personnalisé
US11447566B2 (en) 2018-01-04 2022-09-20 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
WO2022229966A1 (fr) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. Récepteurs des lymphocytes t dirigés contre des néoantigènes récurrents dérivés de ras et leurs procédés d'identification
WO2022229464A1 (fr) 2021-04-30 2022-11-03 Tigen Pharma Sa Multiplication de lymphocytes dans un seul récipient
US11504421B2 (en) 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
EP3935071A4 (fr) * 2019-03-06 2022-12-21 Gritstone bio, Inc. Identification de néoantigènes au moyen d'un modèle de classe ii du cmh
US11591619B2 (en) 2019-05-30 2023-02-28 Gritstone Bio, Inc. Modified adenoviruses
US11771747B2 (en) 2020-08-06 2023-10-03 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
RU2809620C2 (ru) * 2018-11-15 2023-12-13 Ноуском Аг Выбор раковых мутаций для создания персонализированной противораковой вакцины
WO2024097864A1 (fr) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion de lymphocytes

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20160101073A (ko) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016100975A1 (fr) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
US11514289B1 (en) * 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
DK3488443T3 (da) * 2016-07-20 2021-09-27 BioNTech SE Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning
CN106295678B (zh) * 2016-07-27 2020-03-06 北京旷视科技有限公司 神经网络训练与构建方法和装置以及目标检测方法和装置
EP3494231A4 (fr) * 2016-08-02 2020-04-15 Georgetown University Méthodes pour identifier de nouvelles protéines et de nouveaux antigènes dans des cellules cancéreuses
WO2018102613A2 (fr) 2016-12-01 2018-06-07 Nantomics, Llc Présentation et traitement de l'antigénicité tumorale
FI3580561T3 (fi) 2017-02-12 2023-12-12 Biontech Us Inc Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö
EP3568811A1 (fr) * 2017-02-24 2019-11-20 Deepmind Technologies Limited Formation de modèles d'apprentissage automatique
WO2018234506A2 (fr) * 2017-06-21 2018-12-27 Transgene Sa Vaccin personnalisé
WO2019031939A2 (fr) * 2017-08-10 2019-02-14 주식회사 굳티셀 Méthode d'activation des cellules t pour le traitement du cancer
WO2019050994A1 (fr) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. Identification de néoantigène pour une thérapie par lymphocytes t
CN113627458A (zh) 2017-10-16 2021-11-09 因美纳有限公司 基于循环神经网络的变体致病性分类器
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
WO2019079198A1 (fr) * 2017-10-16 2019-04-25 Illumina, Inc. Classification de site de raccordement basée sur un apprentissage profond
KR20200127001A (ko) * 2018-02-27 2020-11-09 그릿스톤 온콜로지, 인코포레이티드 범-대립유전자 모델을 갖는 신생항원 동정
US20210020270A1 (en) * 2018-03-08 2021-01-21 The Trustees Of Indiana University Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry
WO2019200398A1 (fr) * 2018-04-13 2019-10-17 Dana-Farber Cancer Institute, Inc. Détection ultrasensible du cancer par analyse algorithmique
KR102212663B1 (ko) * 2018-05-22 2021-02-05 주식회사 석영시스템즈 목표 온도를 기반으로 하는 빌딩의 열·공조 시스템에 대한 공급 전력 제어 방법 및 장치
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
CN112639136A (zh) * 2018-08-30 2021-04-09 蒙特利尔大学 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
WO2020087071A1 (fr) * 2018-10-26 2020-04-30 Dana-Farber Cancer Institute, Inc. Variants génomiques dans des régions de gène ig et leurs utilisations
US20210381060A1 (en) * 2018-10-29 2021-12-09 Health Research, Inc. Cancer specific immunotherapeutic targets generated by chemotherapeutic drug treatment
EP3844756A1 (fr) 2018-11-21 2021-07-07 NEC Corporation Méthode et système de ciblage d'épitopes pour une immunothérapie à base de néoantigènes
WO2020132235A1 (fr) * 2018-12-20 2020-06-25 Merck Sharp & Dohme Corp. Procédés et systèmes pour l'identification précise de néoantigènes tumoraux immunogènes
AU2019404547A1 (en) * 2018-12-21 2021-07-22 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
EP3897691A4 (fr) * 2018-12-21 2022-08-31 The Regents of the University of California Vaccins contenant de l'il-10 et leurs utilisations
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
CN109712672B (zh) * 2018-12-29 2021-05-25 北京优迅医学检验实验室有限公司 检测基因重排的方法、装置、存储介质及处理器
CN110675913B (zh) * 2019-01-16 2022-04-12 倍而达药业（苏州）有限公司 一种基于hla分型与结构的肿瘤新抗原的筛选方法
CN109801678B (zh) * 2019-01-25 2023-07-25 上海鲸舟基因科技有限公司 基于全转录组的肿瘤抗原预测方法及其应用
WO2020167667A1 (fr) * 2019-02-11 2020-08-20 Flagship Pioneering Innovations Vi, Llc Analyse de polypeptides guidée par l'apprentissage automatique
EP3927354A1 (fr) 2019-02-20 2021-12-29 Rubius Therapeutics, Inc. Cellules érythroïdes modifiées comprenant des polypeptides de présentation d'antigène chargeables et procédés d'utilisation
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN111696628A (zh) * 2019-03-15 2020-09-22 痕准生物科技有限公司 新生抗原的鉴定方法
US11599774B2 (en) * 2019-03-29 2023-03-07 International Business Machines Corporation Training machine learning model
CN110172513A (zh) * 2019-05-30 2019-08-27 浙江自贸区锐赛生物医药科技有限公司 突变型免疫多肽临床入组的筛选方法
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
CN110456079B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US20210104294A1 (en) * 2019-10-02 2021-04-08 The General Hospital Corporation Method for predicting hla-binding peptides using protein structural features
EP4116436A4 (fr) * 2020-01-07 2024-01-31 Korea Advanced Institute of Science and Technology Procédé et système de criblage de néoantigènes et leurs utilisations
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
EP4143830A1 (fr) * 2020-04-27 2023-03-08 Flagship Pioneering Innovations VI, LLC Optimisation de protéines à l'aide d'optimisations fondées sur un modèle
EP4153730A1 (fr) * 2020-05-19 2023-03-29 Gritstone bio, Inc. Vaccins contre le sars-cov-2
US20220139498A1 (en) * 2020-11-04 2022-05-05 Basf Corporation Apparatuses, systems, and methods for extracting meaning from dna sequence data using natural language processing (nlp)
US20220319635A1 (en) * 2021-04-05 2022-10-06 Nec Laboratories America, Inc. Generating minority-class examples for training data
CN113129998B (zh) * 2021-04-23 2022-06-21 云测智能科技有限公司 临床个体化肿瘤新抗原的预测模型构建方法
CN113762416B (zh) * 2021-10-15 2023-05-30 南京澄实生物科技有限公司 基于多模态深度编码的抗原免疫原性预测方法和系统
CN113807468B (zh) * 2021-10-15 2022-05-27 南京澄实生物科技有限公司 基于多模态深度编码的hla抗原呈递预测方法和系统
WO2023177655A1 (fr) 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
TWI805290B (zh) * 2022-03-28 2023-06-11 臺北醫學大學 用於預測肺腺癌是否具有表皮生長因子受體突變的方法
US20230368872A1 (en) * 2022-05-16 2023-11-16 Spencer Health Solutions, Llc Alert decision support system based on patient quality of life survey information and related methods and computer program products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110293637A1 (en) * 2010-05-14 2011-12-01 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2015095811A2 (fr) * 2013-12-20 2015-06-25 The Board Institute Inc. Polythérapie comprenant un vaccin à base de néoantigènes

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0434792A4 (en) 1989-05-19 1992-05-20 John B. Fenn Multiply charged ions and a method for determining the molecular weight of large molecules
US5130538A (en) 1989-05-19 1992-07-14 John B. Fenn Method of producing multiply charged ions and for determining molecular weights of molecules by use of the multiply charged ions of molecules
US5581080A (en) 1989-05-19 1996-12-03 Fenn; John B. Method for determining molecular weight using multiply charged ions
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
WO1991013167A1 (fr) 1990-02-26 1991-09-05 The Board Of Trustees Of The Leland Stanford Junior University Identification et expression de sequences d'adn de recepteurs de steroides d'insectes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5608217A (en) 1994-03-10 1997-03-04 Bruker-Franzen Analytik Gmbh Electrospraying method for mass spectrometric analysis
DE4444229C2 (de) 1994-03-10 1996-07-25 Bruker Franzen Analytik Gmbh Verfahren und Vorrichtungen zur Elektrosprüh-Ionisierung für speichernde Massenspektometer
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
JP2001520013A (ja) 1997-10-10 2001-10-30 ビーエーエスエフ アクチェンゲゼルシャフト Ｔ細胞受容体−会合分子（ｔａｒｍｓ）及びその使用方法
DE19937828C1 (de) 1999-08-11 2000-10-05 Smb Schwede Maschinenbau Gmbh Schweißkopf für eine Bandumreifungsmaschine
WO2001025268A1 (fr) 1999-10-04 2001-04-12 Schrotz King Petra Proteines humaines associees a l'attaque
MXPA02009157A (es) 2000-03-22 2004-04-05 Rohm & Haas Nuevo sistema de expresion genetica inducible a base del receptor de ecdisona.
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
DE60135315D1 (de) * 2000-04-04 2008-09-25 Univ Rochester In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
WO2001094935A2 (fr) 2000-06-09 2001-12-13 Mds Proteomics, Inc. Etiquetage d'echantillons proteomiques pendant la proteolyse a des fins de quantification et d'analyse multiple d'echantillons
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
WO2002037121A2 (fr) 2000-10-25 2002-05-10 Mds Proteomics, Inc. Detection d'acides amines modifies par spectrometrie de masse
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
EP1419518A2 (fr) 2001-04-09 2004-05-19 MDS Proteomics Inc. Methodes et systemes de recherche de bases de donnees genomiques
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US20040002112A1 (en) 2001-10-31 2004-01-01 Matthias Mann Proteins involved in regulation of adipocytes and uses related thereto
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2003087162A2 (fr) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides et procedes utilises dans la detection et le traitement du cancer
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
AU2004268497A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
MXPA06007144A (es) 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20070265818A1 (en) 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (fr) 2006-02-27 2010-05-19 Univ Arizona Identification et utilisation de novopeptides pour le traitement du cancer
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
SI1991263T1 (sl) 2006-03-01 2015-03-31 Aduro Biotech Listeria spremenjena z inĹľeniringom ter postopki za njenjo uporabo
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
DE102006032362A1 (de) 2006-07-13 2008-01-17 Khd Humboldt Wedag Gmbh Rollenpresse insbesondere zur Gutbettzerkleinerung
WO2008094188A2 (fr) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Procédés et compositions utilisant la listeria pour renforcer l'immunogénicité par primo-immunisation
US8121797B2 (en) 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
HUE026142T2 (en) 2007-07-27 2016-05-30 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
CN101765434B (zh) 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 抗肿瘤相关肽及相关抗癌疫苗组合物
MX2010001086A (es) 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
WO2009034190A2 (fr) 2007-09-14 2009-03-19 Genimmune N.V. Marqueur d'affinité
EP2060583A1 (fr) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
NO2227271T3 (fr) 2007-12-07 2018-06-23
EP2091046A1 (fr) 2008-02-15 2009-08-19 Thomson Licensing Système de présentation et son procédé de commande
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
EP2288379A4 (fr) 2008-05-19 2012-08-08 Advaxis Système de double distribution pour des antigènes hétérologues
CA2724649A1 (fr) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procedes d'utilisation
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2010104747A2 (fr) 2009-03-10 2010-09-16 Baylor Research Institute Vaccins ciblés vers des cellules présentant des antigènes
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2010028288A2 (fr) 2008-09-05 2010-03-11 Aueon, Inc. Procédés pour la stratification et l’annotation des options de traitement médicamenteux contre le cancer
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
LT2865387T (lt) 2008-11-21 2019-09-25 Kobenhavns Universitet (University Of Copenhagen) Imuninio atsako sužadinimas
PL2403528T3 (pl) 2009-03-02 2017-08-31 Aduro Biotech Holdings, Europe B.V. Przeciwciała przeciwko ligandowi indukującemu proliferację (APRIL)
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
WO2010115118A2 (fr) 2009-04-03 2010-10-07 Antigenics, Inc. Procédés de préparation et d'utilisation de complexes chaperons multiples-antigène
EP2309262A1 (fr) 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour la quantification de biomolécules
JP5985397B2 (ja) 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
WO2011100754A1 (fr) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
CN102947452A (zh) 2010-05-23 2013-02-27 艾杜罗生物科技公司 使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物
CA2800535A1 (fr) 2010-05-24 2011-12-01 Phosimmune, Inc. Phosphopeptides du cmh de classe i pour l'immunotherapie et le diagnostic du cancer
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
US20130303594A1 (en) 2010-09-14 2013-11-14 Max-Planok-Gesellschaft Zur Forderung Der Wissenschaften E.V. Hot1 and uses thereof
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
HUE039747T2 (hu) 2010-11-17 2019-02-28 Aduro Biotech Inc Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CA2823621C (fr) 2010-12-30 2023-04-25 Foundation Medicine, Inc. Optimisation d'analyse multigenique d'echantillons de tumeur
EP3332804A1 (fr) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvants à base de listeria
EP2508537A1 (fr) 2011-04-04 2012-10-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Étalon quantitatif pour la spectrométrie de masse de protéines
SI3892295T1 (sl) 2011-05-24 2023-09-29 BioNTech SE Individualizirana cepiva proti raku
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2013158611A1 (fr) 2012-04-16 2013-10-24 Agenus Inc. Méthodes et compositions destinées à traiter les glioblastomes
CN104662171B (zh) 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
WO2014039718A1 (fr) 2012-09-05 2014-03-13 Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz Procédés de découverte de cibles thérapeutiques
AU2013347184B2 (en) 2012-11-13 2018-06-14 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
WO2014082729A1 (fr) 2012-11-28 2014-06-05 Biontech Ag Vaccins individualisés contre le cancer
MX361680B (es) 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
CA2895578A1 (fr) 2012-12-19 2014-06-26 Nils A. KULAK Reacteur pour preparation d'echantillon
CN104955835B (zh) 2012-12-27 2020-04-17 艾杜罗生物科技公司 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
CA2901115A1 (fr) 2013-02-15 2014-08-21 The Regents Of The University Of California Recepteur antigenique chimerique heterodimere conditionnellement actif et procede d'utilisation
KR102341899B1 (ko) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
PL2996473T3 (pl) 2013-05-18 2020-06-01 Aduro Biotech, Inc. Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
US11069427B2 (en) * 2013-06-10 2021-07-20 Iogenetics, Llc Mathematical processes for determination of peptidase cleavage
AU2014298504B2 (en) 2013-07-30 2018-08-30 Biontech Ag Tumor antigens for determining cancer therapy
EP3777882A1 (fr) 2013-07-30 2021-02-17 BioNTech SE Antigenes de tumeur pour determiner la therapie du cancer
EP3027210A1 (fr) 2013-08-02 2016-06-08 Aduro Biotech Holdings, Europe B.V. Combinaison d'agonistes cd27 et d'inhibiteurs de points de contrôle immunitaires pour une stimulation immune
TWI777197B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六）
AU2014310606B2 (en) 2013-08-19 2020-03-05 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of tumors
EP2959021B1 (fr) 2013-08-19 2018-08-08 BioNTech Diagnostics GmbH Méthodes et kits pour le sous-typage moléculaire de tumeurs
WO2015030585A2 (fr) 2013-08-27 2015-03-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Procédés pour détecter des lysines ayant subi une modification post-traductionnelle dans un polypeptide
CA2921639A1 (fr) 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Peptides se liant a la proteine cd70 et procede, processus et utilisation associes
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2015043613A1 (fr) 2013-09-26 2015-04-02 Biontech Ag Particules comprenant une coque contenant de l'arn
EP3060679B1 (fr) 2013-10-25 2019-06-12 BioNTech Diagnostics GmbH Méthode et trousse pour déterminer si un sujet présente une réponse immunitaire
WO2015058780A1 (fr) 2013-10-25 2015-04-30 Biontech Ag Méthode et kit pour déterminer si un patient présente une réponse immunitaire
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
SG10201805674YA (en) 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
KR20160113158A (ko) * 2014-01-27 2016-09-28 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
WO2015113140A1 (fr) 2014-01-29 2015-08-06 University Health Network Procédés et compositions permettant la production d'une cellule exprimant un récepteur de l'antigène des lymphocytes t
US10858415B2 (en) 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
CA2947358A1 (fr) 2014-02-18 2015-08-27 Advaxis, Inc. Immunotherapie multi-cibles dirigee contre un biomarqueur
JP2017507943A (ja) 2014-02-25 2017-03-23 アドバクシス， インコーポレイテッド Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法
AU2015227163A1 (en) 2014-03-05 2016-10-20 Advaxis, Inc. Methods and compositions for increasing a T-effector cell to regulatory T cell ratio
US20150278441A1 (en) * 2014-03-25 2015-10-01 Nec Laboratories America, Inc. High-order semi-Restricted Boltzmann Machines and Deep Models for accurate peptide-MHC binding prediction
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP2944955A1 (fr) 2014-05-13 2015-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Étalon pour systèmes LC-MS
WO2015172843A1 (fr) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Méthodes et kits destinés au diagnostic du cancer
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
US10000533B2 (en) 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
WO2016011320A1 (fr) 2014-07-18 2016-01-21 Advaxis, Inc. Système de largage d'antigènes hétérologues bivalent dérivé de listéria
US20180064765A1 (en) 2014-07-18 2018-03-08 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
WO2016011357A1 (fr) 2014-07-18 2016-01-21 Advaxis, Inc. Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
AU2015315005B9 (en) 2014-09-10 2021-08-12 Genentech, Inc. Immunogenic mutant peptide screening platform
AU2015314776A1 (en) 2014-09-14 2017-04-06 Washington University Personalized cancer vaccines and methods therefor
JP6672310B2 (ja) 2014-09-15 2020-03-25 アブビトロ， エルエルシー ハイスループットヌクレオチドライブラリーシークエンシング
KR20170078619A (ko) 2014-09-17 2017-07-07 더 존스 홉킨스 유니버시티 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법
EP3201322A4 (fr) 2014-10-03 2018-05-30 Yale University Modification du systeme immunitaire inne pour une therapie anticancereuse
WO2016062323A1 (fr) 2014-10-20 2016-04-28 Biontech Ag Methodes et compositions de diagnostic et de traitement du cancer
AU2015339744B2 (en) 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
DE102014116335A1 (de) 2014-11-10 2016-05-12 Thyssenkrupp Ag Verbundwerkstoff, Verbundwerkstoffprodukt, Verfahren zu deren Herstellung und Verwendungen dafür
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
WO2016100975A1 (fr) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
WO2016100977A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Procédés pour le profilage du répertoire de récepteurs de cellules t
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
RS63384B1 (sr) 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126876A2 (fr) 2015-02-03 2016-08-11 Advaxis, Inc. Adjuvants à base de listeria
EP3256846A1 (fr) 2015-02-09 2017-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Moyen et procédés de réduction au minimum de volume balayé et de volume mort dans des applications chromatographiques
WO2016128060A1 (fr) 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination
ES2914180T3 (es) 2015-02-17 2022-06-07 Biontech Diagnostics Gmbh Procedimientos y kits para la subtipificación molecular del cáncer de vejiga
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3267969A1 (fr) 2015-03-09 2018-01-17 King's College London Polythérapie avec des agonistes alpha de rar pour améliorer une réponse de type th1
WO2016145578A1 (fr) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Procédés de traitement du cancer au moyen de lymphocytes t activés
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2016154412A2 (fr) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement d'un cancer du pancréas
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2016155809A1 (fr) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Formulations de particules lipidiques permettant la délivrance à une cellule cible d'arn et de composés hydrosolubles thérapeutiquement efficaces
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
EP3283100A2 (fr) 2015-04-13 2018-02-21 Aduro Biotech, Inc. Protéines de fusion immunogènes pour le traitement du cancer
MX2017013174A (es) 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
US20180318347A1 (en) 2015-04-22 2018-11-08 Agenus Inc. Methods for treating cancer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
IL298497A (en) 2015-04-27 2023-01-01 Cancer Research Tech Ltd A method for treating cancer
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
WO2016180467A1 (fr) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Renforcement de l'effet de lymphocytes t génétiquement modifiés par car, par vaccination par acide nucléique
MA42420A (fr) 2015-05-13 2018-05-23 Agenus Inc Vaccins pour le traitement et la prévention du cancer
WO2016183361A1 (fr) 2015-05-13 2016-11-17 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des protéines hybrides d'acta tronqué-antigène et procédés d'utilisation de ces compositions
CN116196401A (zh) 2015-05-20 2023-06-02 博德研究所 共有的新抗原
US10293637B2 (en) 2015-05-21 2019-05-21 Burley Design Llc Bicycle quick release cam lever with biased closure
MX2017015149A (es) 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
CN113603784A (zh) 2015-05-29 2021-11-05 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
EP3313975A4 (fr) 2015-06-24 2019-03-13 Advaxis, Inc. Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
EP3115369A1 (fr) 2015-07-09 2017-01-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Purification de peptides utilisant un matériau d'extraction en phase solide à phase mixte
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
AU2016299304B2 (en) 2015-07-29 2020-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for a sample preparation, especially for mass spectrometry
WO2017024006A1 (fr) 2015-08-03 2017-02-09 The Johns Hopkins University Thérapie cellulaire allogénique personnalisée du cancer
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017030956A1 (fr) 2015-08-14 2017-02-23 Agenus Inc. Procédé d'induction d'une réponse des lymphocytes t à des phosphopeptides à l'aide d'acides nucléiques codant pour des mimétiques de phosphopeptides
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170136108A1 (en) 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
MX2018002315A (es) 2015-09-01 2018-04-11 Agenus Inc Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
MX2018004544A (es) 2015-10-12 2018-11-09 Nantomics Llc Composiciones y métodos para los neoepítopos de cáncer viral.
US10546650B2 (en) * 2015-10-23 2020-01-28 Google Llc Neural network for processing aptamer data
EP3390434A2 (fr) 2015-12-14 2018-10-24 Bellicum Pharmaceuticals, Inc. Doubles commandes pour l'activation ou l'élimination de cellules thérapeutiques
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
US10497089B2 (en) * 2016-01-29 2019-12-03 Fotonation Limited Convolutional neural network
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3544607A4 (fr) 2016-11-23 2020-10-14 Gritstone Oncology, Inc. Administration virale de néo-antigènes
KR20180063481A (ko) 2016-12-02 2018-06-12 주식회사 원소프트다임 체지방을 측정하는 클라우드 기반 휴대용 장치를 이용하여 헬스케어 정보를 제공하는 방법 및 이를 이용하는 장치
TWI672503B (zh) * 2017-03-31 2019-09-21 行動基因生技股份有限公司 致免疫性之癌症特異抗原決定位的排名系統
SG11201909652WA (en) 2017-04-19 2019-11-28 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
SG11201911620PA (en) 2017-06-09 2020-01-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
WO2019050994A1 (fr) 2017-09-05 2019-03-14 Gritstone Oncology, Inc. Identification de néoantigène pour une thérapie par lymphocytes t
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR20200127001A (ko) 2018-02-27 2020-11-09 그릿스톤 온콜로지, 인코포레이티드 범-대립유전자 모델을 갖는 신생항원 동정

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110293637A1 (en) * 2010-05-14 2011-12-01 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2015095811A2 (fr) * 2013-12-20 2015-06-25 The Board Institute Inc. Polythérapie comprenant un vaccin à base de néoantigènes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: "Prediction of HLA-DQ8 beta Cell Peptidome Using a Computational Program and i Relationship to Autoreactive T Cells", INTERNATIONAL IMMUNOLOGY, vol. 21, 1 June 2009 (2009-06-01), pages 705 - 713, XP055394206 *
FRITSCH ET AL.: "HLA-Binding Properties of Tumor Neoepitopes in Humans", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 6, 1 June 2014 (2014-06-01), pages 522 - 529, XP002762399 *
LORENTE ET AL.: "Diversity of Natural Self-Derived Ligands Presented by Different HLA Class I Molecules in Transporter Antigen Processing-Deficient Cells", PLOS ONE, vol. 8, no. 3, 26 March 2013 (2013-03-26), pages 1 - 10, XP055394207 *
PRITCHARD ET AL.: "Exome Sequencing to Predict Neoantigens in Melanoma", CANCER IMMUNOLOGY RESEARCH, vol. 3, 1 September 2015 (2015-09-01), pages 992 - 998, XP055394209 *
SURI ET AL.: "Specificity of Peptide Selection by Antigen-Presenting Cells Homozygous or Heterozygous for Expression of Class II MHC Molecules: the Lack of Competition", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES, vol. 100, 29 April 2003 (2003-04-29), pages 5330 - 5335, XP055394203 *
YADAV ET AL.: "Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing", NATURE, vol. 515, 27 November 2014 (2014-11-27), pages 572 - 576, XP055364790 *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11222711B2 (en) 2013-05-10 2022-01-11 BioNTech SE Predicting immunogenicity of T cell epitopes
US11156617B2 (en) 2015-02-12 2021-10-26 BioNTech RNA Pharmaceuticals GbmH Predicting T cell epitopes useful for vaccination
US10847253B2 (en) 2015-12-16 2020-11-24 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US10847252B2 (en) 2015-12-16 2020-11-24 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US11183286B2 (en) 2015-12-16 2021-11-23 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
WO2018136664A1 (fr) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Néoantigènes et leurs utilisations dans le traitement du cancer
WO2018195357A1 (fr) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Identification de néoantigènes, fabrication et utilisation
US11510973B2 (en) 2017-05-08 2022-11-29 Gritstone Bio, Inc. Alphavirus antigen vectors
US11504421B2 (en) 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
WO2019006022A1 (fr) * 2017-06-27 2019-01-03 The Broad Institute, Inc. Systèmes et procédés de prédiction d'épitope du cmh de classe ii
CN110913896A (zh) * 2017-07-14 2020-03-24 弗朗西斯.克里克研究所 肿瘤中hla等位基因的分析及其用途
US11634773B2 (en) 2017-07-14 2023-04-25 The Francis Crick Institute Limited Analysis of HLA alleles in tumours and the uses thereof
WO2019012296A1 (fr) * 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analyse d'allèles hla dans des tumeurs et utilisations associées
JP2020529470A (ja) * 2017-07-25 2020-10-08 カリフォルニア インスティチュート オブ テクノロジー トロゴサイトーシス媒介エピトープ発見
CN111727262A (zh) * 2017-07-25 2020-09-29 加州理工学院 胞啃介导的表位发现
EP3658683A4 (fr) * 2017-07-25 2021-04-21 California Institute of Technology Découverte d'épitopes à médiation par trogocytose
JP2019030275A (ja) * 2017-08-09 2019-02-28 学校法人日本大学 口臭判定装置及びプログラム
US11264117B2 (en) 2017-10-10 2022-03-01 Gritstone Bio, Inc. Neoantigen identification using hotspots
WO2019075112A1 (fr) * 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Identification de néo-antigènes au moyen de points chauds
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
JP2021503897A (ja) * 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
CN109682978A (zh) * 2017-11-30 2019-04-26 丁平 一种肿瘤突变肽mhc亲和力预测方法及其应用
US11447566B2 (en) 2018-01-04 2022-09-20 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
JP2021525076A (ja) * 2018-05-23 2021-09-24 グリットストーン バイオ インコーポレイテッド 共有抗原
CN112368386A (zh) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
WO2020022897A1 (fr) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Procédé de préparation de compositions immunogènes spécifiques à un sujet en s'appuyant sur une base de données de néo-peptides à cadre ouvert de lecture
WO2020072700A1 (fr) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
TWI818101B (zh) * 2018-11-01 2023-10-11 日商濱松赫德尼古斯股份有限公司 頻譜分析裝置及頻譜分析方法
JP7239300B2 (ja) 2018-11-01 2023-03-14 浜松ホトニクス株式会社 スペクトル分析装置およびスペクトル分析方法
JP2020071166A (ja) * 2018-11-01 2020-05-07 浜松ホトニクス株式会社 スペクトル分析装置およびスペクトル分析方法
WO2020090336A1 (fr) * 2018-11-01 2020-05-07 浜松ホトニクス株式会社 Dispositif d'analyse de spectre et procédé d'analyse de spectre
WO2020099614A1 (fr) * 2018-11-15 2020-05-22 Nouscom Ag Sélection de mutations de cancer pour la génération d'un vaccin personnalisé contre le cancer
RU2809620C2 (ru) * 2018-11-15 2023-12-13 Ноуском Аг Выбор раковых мутаций для создания персонализированной противораковой вакцины
JP2022513047A (ja) * 2018-11-15 2022-02-07 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択
JP7477888B2 (ja) 2018-11-15 2024-05-02 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択
WO2020141207A1 (fr) 2019-01-03 2020-07-09 Evaxion Biotech Aps Vaccins ciblant des néo-épitopes
WO2020157760A1 (fr) * 2019-01-31 2020-08-06 Bar Ilan University Néo-antigènes créés par épissage aberrant induit et leurs utilisations dans l'amélioration de l'immunothérapie
EP3935071A4 (fr) * 2019-03-06 2022-12-21 Gritstone bio, Inc. Identification de néoantigènes au moyen d'un modèle de classe ii du cmh
WO2020182901A1 (fr) 2019-03-11 2020-09-17 Evaxion Biotech Aps Vaccination par acides nucléiques au moyen de constructions de codage de néoépitopes
US11591619B2 (en) 2019-05-30 2023-02-28 Gritstone Bio, Inc. Modified adenoviruses
CN114340661A (zh) * 2019-07-02 2022-04-12 磨石生物公司 Hiv抗原和mhc复合物
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021048400A1 (fr) 2019-09-13 2021-03-18 Evaxion Biotech Aps Procédé d'identification d'épitopes de lymphocytes t
WO2021123232A1 (fr) 2019-12-18 2021-06-24 Evaxion Biotech Aps Vaccination par acides nucléiques au moyen de constructions codant pour des néo-épitopes
WO2021204911A1 (fr) 2020-04-07 2021-10-14 Evaxion Biotech A/S Immunothérapie par néo-épitope avec unité de ciblage apc
WO2022013154A1 (fr) 2020-07-14 2022-01-20 Myneo Nv Procédé, système et produit de programme d'ordinateur permettant de déterminer des probabilités de présentation de néoantigènes
WO2022013277A1 (fr) 2020-07-14 2022-01-20 Evaxion Biotech A/S Unités de ciblage de cpa pour immunothérapie
US11771747B2 (en) 2020-08-06 2023-10-03 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022098936A1 (fr) * 2020-11-06 2022-05-12 Amazon Technologies, Inc. Sélection de néo-antigènes pour un vaccin anticancéreux personnalisé
WO2022229966A1 (fr) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. Récepteurs des lymphocytes t dirigés contre des néoantigènes récurrents dérivés de ras et leurs procédés d'identification
WO2022229464A1 (fr) 2021-04-30 2022-11-03 Tigen Pharma Sa Multiplication de lymphocytes dans un seul récipient
WO2024097864A1 (fr) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion de lymphocytes

Also Published As

Publication number Publication date
AU2016369519A1 (en) 2018-07-12
AU2023204618A1 (en) 2023-08-03
US10847253B2 (en) 2020-11-24
IL259931B2 (en) 2024-02-01
AU2016369519B2 (en) 2023-04-20
IL259931B1 (en) 2023-10-01
RU2018124997A3 (fr) 2020-05-29
MX2023014124A (es) 2023-12-12
SG11201804957VA (en) 2018-07-30
US20210098077A1 (en) 2021-04-01
ES2970865T3 (es) 2024-05-31
RU2018124997A (ru) 2020-01-16
US10055540B2 (en) 2018-08-21
US10847252B2 (en) 2020-11-24
US20170199961A1 (en) 2017-07-13
CO2018007417A2 (es) 2018-09-28
EP3389630A1 (fr) 2018-10-24
TWI765875B (zh) 2022-06-01
CA3008641A1 (fr) 2017-06-22
PH12018501267A1 (en) 2019-02-11
MX2018007204A (es) 2018-12-11
HK1257865A1 (zh) 2019-11-01
JP7114477B2 (ja) 2022-08-08
EP3389630A4 (fr) 2020-01-01
US20190034585A1 (en) 2019-01-31
EP4299136A3 (fr) 2024-02-14
EP4299136A2 (fr) 2024-01-03
IL305238A (en) 2023-10-01
KR20180107102A (ko) 2018-10-01
CN108601731A (zh) 2018-09-28
PE20181535A1 (es) 2018-09-26
US20210166784A1 (en) 2021-06-03
JP2019501967A (ja) 2019-01-24
US11183286B2 (en) 2021-11-23
US20170212984A1 (en) 2017-07-27
IL259931A (en) 2018-07-31
EP3389630B1 (fr) 2023-11-08
JP2022133271A (ja) 2022-09-13
TW201733598A (zh) 2017-10-01
US20190065675A1 (en) 2019-02-28
BR112018012374A2 (pt) 2018-12-04
RU2729116C2 (ru) 2020-08-04
US20180330055A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
AU2016369519B2 (en) Neoantigen identification, manufacture, and use
AU2018254526B2 (en) Neoantigen identification, manufacture, and use
AU2018279627B2 (en) Neoantigen identification, manufacture, and use
US11885815B2 (en) Reducing junction epitope presentation for neoantigens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16876766

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 259931

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11201804957V

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/007204

Country of ref document: MX

Ref document number: 12018501267

Country of ref document: PH

Ref document number: 001119-2018

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 3008641

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018550664

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018012374

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016369519

Country of ref document: AU

Date of ref document: 20161216

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187020164

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016876766

Country of ref document: EP

Ref document number: 2018124997

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2016876766

Country of ref document: EP

Effective date: 20180716

ENP Entry into the national phase

Ref document number: 112018012374

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180618